

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the quarterly period ended June 27, 2025

Or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File No.: 001-35083

**NOVANTA INC.**

(Exact name of registrant as specified in its charter)

**New Brunswick, Canada**  
(State or other jurisdiction of incorporation or organization)

**98-0110412**

(I.R.S. Employer Identification No.)

**125 Middlesex Turnpike, Bedford, Massachusetts, USA**  
(Address of principal executive offices)

**01730**  
(Zip Code)

**Registrant's telephone number, including area code: (781) 266-5700**

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common shares, no par value	NOVT	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES  NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES  NO

As of July 28, 2025, there were 35,973,631 of the Registrant's common shares, no par value, issued and outstanding.

NOVANTA INC.  
TABLE OF CONTENTS

<u>Item No.</u>		<u>Page No.</u>
<u>PART I — FINANCIAL INFORMATION</u>		
ITEM 1.	<u>FINANCIAL STATEMENTS</u>	1
	<u>CONSOLIDATED BALANCE SHEETS (unaudited)</u>	1
	<u>CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</u>	2
	<u>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited)</u>	3
	<u>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited)</u>	4
	<u>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</u>	5
	<u>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</u>	6
ITEM 2.	<u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	30
ITEM 3.	<u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>	41
ITEM 4.	<u>CONTROLS AND PROCEDURES</u>	41
<u>PART II — OTHER INFORMATION</u>		
ITEM 1.	<u>LEGAL PROCEEDINGS</u>	42
ITEM 1A.	<u>RISK FACTORS</u>	42
ITEM 2.	<u>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</u>	42
ITEM 3.	<u>DEFAULTS UPON SENIOR SECURITIES</u>	42
ITEM 4.	<u>MINE SAFETY DISCLOSURES</u>	43
ITEM 5.	<u>OTHER INFORMATION</u>	43
ITEM 6.	<u>EXHIBITS</u>	44
<u>SIGNATURES</u>		45

---

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

NOVANTA INC.  
CONSOLIDATED BALANCE SHEETS  
(In thousands of U.S. dollars or shares)  
(Unaudited)

	June 27, 2025	December 31, 2024
<b>ASSETS</b>		
Current assets		
Cash and cash equivalents	\$ 109,912	\$ 113,989
Accounts receivable, net of allowance of \$610 and \$505, respectively	161,202	151,026
Inventories	168,065	144,606
Prepaid income taxes and income taxes receivable	8,160	8,076
Prepaid expenses and other current assets	14,761	15,951
Total current assets	462,100	433,648
Property, plant and equipment, net	118,876	113,135
Operating lease assets	44,107	42,908
Deferred tax assets	26,980	22,887
Other assets	6,283	5,991
Intangible assets, net	203,630	185,844
Goodwill	649,093	584,098
Total assets	<u>\$ 1,511,069</u>	<u>\$ 1,388,511</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities		
Current portion of long-term debt	\$ 5,203	\$ 4,691
Accounts payable	88,973	76,890
Income taxes payable	12,937	16,000
Current portion of operating lease liabilities	10,302	9,879
Accrued expenses and other current liabilities	64,523	60,331
Total current liabilities	181,938	167,791
Long-term debt	454,037	411,949
Operating lease liabilities	41,086	40,548
Deferred tax liabilities	20,776	13,093
Income taxes payable	4,971	4,941
Other liabilities	6,815	4,491
Total liabilities	709,623	642,813
Commitments and contingencies (Note 15)		
Stockholders' equity:		
Preferred shares, no par value; Authorized shares: 7,000; No shares issued and outstanding	—	—
Common shares, no par value; Authorized shares: unlimited; Issued and outstanding: 35,973 and 35,938, respectively	423,856	423,856
Additional paid-in capital	85,468	84,214
Retained earnings	293,254	267,549
Accumulated other comprehensive loss	(1,132)	(29,921)
Total stockholders' equity	801,446	745,698
Total liabilities and stockholders' equity	<u>\$ 1,511,069</u>	<u>\$ 1,388,511</u>

The accompanying notes are an integral part of these consolidated financial statements.

**NOVANTA INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
(In thousands of U.S. dollars or shares, except per share amounts)  
(Unaudited)

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Revenue	\$ 241,049	\$ 235,864	\$ 474,415	\$ 466,780
Cost of revenue	134,303	132,175	263,315	262,675
Gross profit	<u>106,746</u>	<u>103,689</u>	<u>211,100</u>	<u>204,105</u>
Operating expenses:				
Research and development and engineering	25,289	23,731	48,527	46,977
Selling, general and administrative	47,103	44,793	92,699	88,323
Amortization of purchased intangible assets	6,871	6,907	12,425	12,657
Restructuring, acquisition, and related costs	12,572	2,543	10,117	4,826
Total operating expenses	<u>91,835</u>	<u>77,974</u>	<u>163,768</u>	<u>152,783</u>
Operating income	14,911	25,715	47,332	51,322
Interest income (expense), net	(5,815)	(8,266)	(11,459)	(16,520)
Foreign exchange transaction gains (losses), net	(2,744)	(264)	(3,112)	(585)
Other income (expense), net	(563)	(55)	(554)	(171)
Income before income taxes	5,789	17,130	32,207	34,046
Income tax provision	1,292	3,375	6,502	5,615
Net income	<u>\$ 4,497</u>	<u>\$ 13,755</u>	<u>\$ 25,705</u>	<u>\$ 28,431</u>
Earnings per common share (Note 5):				
Basic	\$ 0.12	\$ 0.38	\$ 0.71	\$ 0.79
Diluted	\$ 0.12	\$ 0.38	\$ 0.71	\$ 0.79
Weighted average common shares outstanding—basic	36,022	35,946	36,023	35,930
Weighted average common shares outstanding—diluted	36,076	36,092	36,103	36,110

The accompanying notes are an integral part of these consolidated financial statements.

**NOVANTA INC.**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**  
(In thousands of U.S. dollars)  
(Unaudited)

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Net income	\$ 4,497	\$ 13,755	\$ 25,705	\$ 28,431
Other comprehensive income (loss):				
Foreign currency translation adjustments, net of tax <sup>(1)</sup>	20,399	580	28,957	(3,816)
Pension liability adjustments, net of tax <sup>(2)</sup>	(185)	187	(168)	470
Total other comprehensive income (loss)	20,214	767	28,789	(3,346)
Total consolidated comprehensive income	<u>\$ 24,711</u>	<u>\$ 14,522</u>	<u>\$ 54,494</u>	<u>\$ 25,085</u>

<sup>(1)</sup> The tax effect on this component of comprehensive income (loss) was nominal for all periods presented.

<sup>(2)</sup> The tax effect on this component of comprehensive income (loss) was nominal for all periods presented. See Note 4 to the Consolidated Financial Statements for the total amount of pension liability adjustments reclassified out of accumulated other comprehensive income (loss).

The accompanying notes are an integral part of these consolidated financial statements.

**NOVANTA INC.**  
**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**  
(In thousands of U.S. dollars or shares)  
(Unaudited)

	Common Shares		Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	# of Shares	Amount				
<b>Three Months Ended June 27, 2025</b>						
<b>Balance at March 28, 2025</b>	35,964	\$ 423,856	\$ 78,488	\$ 288,757	\$ (21,346)	\$ 769,755
Net income	—	—	—	4,497	—	4,497
Common shares issued under stock plans	13	—	—	—	—	—
Common shares withheld for taxes on vested stock awards	(4)	—	(518)	—	—	(518)
Share-based compensation	—	—	7,498	—	—	7,498
Other comprehensive income (loss), net of tax	—	—	—	—	20,214	20,214
<b>Balance at June 27, 2025</b>	<u>35,973</u>	<u>\$ 423,856</u>	<u>\$ 85,468</u>	<u>\$ 293,254</u>	<u>\$ (1,132)</u>	<u>\$ 801,446</u>
<b>Six Months Ended June 27, 2025</b>						
<b>Balance at December 31, 2024</b>	35,938	\$ 423,856	\$ 84,214	\$ 267,549	\$ (29,921)	\$ 745,698
Net income	—	—	—	25,705	—	25,705
Common shares issued under stock plans	132	—	—	—	—	—
Common shares withheld for taxes on vested stock awards	(51)	—	(7,187)	—	—	(7,187)
Repurchases of common shares	(46)	—	(6,157)	—	—	(6,157)
Share-based compensation	—	—	14,598	—	—	14,598
Other comprehensive income (loss), net of tax	—	—	—	—	28,789	28,789
<b>Balance at June 27, 2025</b>	<u>35,973</u>	<u>\$ 423,856</u>	<u>\$ 85,468</u>	<u>\$ 293,254</u>	<u>\$ (1,132)</u>	<u>\$ 801,446</u>
<b>Three Months Ended June 28, 2024</b>						
<b>Balance at March 29, 2024</b>	35,891	\$ 423,856	\$ 67,872	\$ 218,138	\$ (28,151)	\$ 681,715
Net income	—	—	—	13,755	—	13,755
Common shares issued under stock plans	7	—	—	—	—	—
Common shares withheld for taxes on vested stock awards	(3)	—	(476)	—	—	(476)
Share-based compensation	—	—	6,231	—	—	6,231
Other comprehensive income (loss), net of tax	—	—	—	—	767	767
<b>Balance at June 28, 2024</b>	<u>35,895</u>	<u>\$ 423,856</u>	<u>\$ 73,627</u>	<u>\$ 231,893</u>	<u>\$ (27,384)</u>	<u>\$ 701,992</u>
<b>Six Months Ended June 28, 2024</b>						
<b>Balance at December 31, 2023</b>	35,814	\$ 423,856	\$ 70,180	\$ 203,462	\$ (24,038)	\$ 673,460
Net income	—	—	—	28,431	—	28,431
Common shares issued under stock plans	136	—	—	—	—	—
Common shares withheld for taxes on vested stock awards	(55)	—	(8,861)	—	—	(8,861)
Share-based compensation	—	—	12,308	—	—	12,308
Other comprehensive income (loss), net of tax	—	—	—	—	(3,346)	(3,346)
<b>Balance at June 28, 2024</b>	<u>35,895</u>	<u>\$ 423,856</u>	<u>\$ 73,627</u>	<u>\$ 231,893</u>	<u>\$ (27,384)</u>	<u>\$ 701,992</u>

The accompanying notes are an integral part of these consolidated financial statements.

**NOVANTA INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(In thousands of U.S. dollars)  
(Unaudited)

	Six Months Ended	
	June 27, 2025	June 28, 2024
<b>Cash flows from operating activities:</b>		
Net income	\$ 25,705	\$ 28,431
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	29,144	27,045
Provision for inventory excess and obsolescence	1,690	5,741
Share-based compensation	14,598	12,308
Deferred income taxes	(5,174)	(7,711)
Write-off of unamortized deferred financing costs	426	—
Inventory acquisition fair value adjustments	—	2,777
Loss (gain) on disposal of fixed assets	(4,089)	116
Other	651	748
Changes in assets and liabilities which (used)/provided cash, excluding effects from business acquisitions:		
Accounts receivable	(2,251)	1,223
Inventories	(14,257)	(6,586)
Prepaid income taxes, income taxes receivable, prepaid expenses and other current assets	3,104	1,056
Accounts payable, income taxes payable, accrued expenses and other current liabilities	(3,479)	8,934
Other non-current assets and liabilities	688	(158)
Net cash provided by operating activities	<u>46,756</u>	<u>73,924</u>
<b>Cash flows from investing activities:</b>		
Cash paid for business acquisitions, net of working capital adjustments	(63,173)	(191,200)
Purchases of property, plant and equipment	(7,672)	(11,352)
Proceeds from sale of property, plant and equipment	5,537	—
Net cash used in investing activities	<u>(65,308)</u>	<u>(202,552)</u>
<b>Cash flows from financing activities:</b>		
Borrowings under revolving credit facilities	72,805	198,000
Repayments under term loan and revolving credit facilities	(41,017)	(67,344)
Payments of debt issuance costs	(3,391)	—
Payments of withholding taxes from share-based awards	(7,187)	(8,861)
Repurchases of common shares	(6,157)	—
Other financing activities	(2,952)	(355)
Net cash provided by financing activities	<u>12,101</u>	<u>121,440</u>
Effect of exchange rates on cash and cash equivalents	2,374	605
Decrease in cash and cash equivalents	(4,077)	(6,583)
Cash and cash equivalents, beginning of the period	113,989	105,051
Cash and cash equivalents, end of the period	<u>\$ 109,912</u>	<u>\$ 98,468</u>
<b>Supplemental disclosure of cash flow information:</b>		
Cash paid for interest	\$ 12,090	\$ 16,491
Cash paid for income taxes	\$ 15,090	\$ 8,035
Income tax refunds received	\$ 299	\$ 739

The accompanying notes are an integral part of these consolidated financial statements.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

**1. Basis of Presentation**

Novanta Inc. (collectively with its subsidiaries, referred to as “Novanta”, the “Company”, “we”, “us”, “our”) is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. Novanta combines deep proprietary technology expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to the customers' demanding applications.

The accompanying unaudited interim consolidated financial statements have been prepared by the Company in United States (“U.S.”) dollars and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), the instructions to Form 10-Q and the provisions of Regulation S-X pertaining to interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. have been condensed or omitted. The interim consolidated financial statements and notes included in this report should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. In the opinion of management, these interim consolidated financial statements include all adjustments and accruals of a normal and recurring nature necessary to fairly state the results of the interim periods presented. The results for interim periods are not necessarily indicative of results to be expected for the full year or for any future periods.

The Company’s unaudited interim consolidated financial statements are prepared for each quarterly period ending on the Friday closest to the end of the calendar quarter, with the exception of the fourth quarter which always ends on December 31.

***Use of Estimates***

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Estimates and assumptions are reviewed on an on-going basis and the effects of revisions are reflected in the period in which such revisions are deemed to be necessary. The Company evaluates its estimates based on historical experience, current conditions, and various other assumptions that it believes are reasonable under the circumstances. Actual results could differ significantly from these estimates.

***Recent Accounting Pronouncements***

The following table provides a brief description of recent Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”):

<b>Standard</b>	<b>Description</b>	<b>Effective Date</b>	<b>Effect on the Financial Statements or Other Significant Matters</b>
In October 2023, the FASB issued ASU 2023-06, “Disclosure Improvements: Codification Amendments in Response to SEC’s Disclosure Update and Simplification Initiative.”	ASU 2023-06 clarifies or improves disclosure and presentation requirements of a variety of topics, which allow users to easily compare entities subject to the SEC’s existing disclosure requirements with those entities that were not previously subject to such requirements and align the requirements in the FASB Accounting Standards Codification with the SEC’s regulations.	The effective date for each amendment in ASU 2023-06 will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited.	The Company is currently evaluating the impact of ASU 2023-06 on its consolidated financial statement disclosures.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

<u>Standard</u>	<u>Description</u>	<u>Effective Date</u>	<u>Effect on the Financial Statements or Other Significant Matters</u>
In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) -Improvements to Income Tax Disclosures."	ASU 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid.	The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted.	The amendments in this update affects financial statement disclosure only and, as a result, will have no impact on results of operations, cash flows or financial condition.
In November 2024, the FASB issued ASU 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses."	ASU 2024-03 improves financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at both interim and annual reporting periods.	The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted.	ASU 2024-03 affects financial statement disclosure only and, as a result, will have no impact on results of operations, cash flows or financial condition.

**2. Revenue**

The Company accounts for its revenue transactions in accordance with Accounting Standards Codification ("ASC") Topic 606, "Revenue from Contracts with Customers," which requires entities to recognize revenue in a way that depicts the transfer of control over goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company recognizes revenue when control of promised goods or services is transferred to the customer. The transfer of control generally occurs upon shipment when title and risk of loss pass to the customer. The vast majority of the Company's revenue is generated from the sale of distinct products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for such products, which is generally at contractually stated prices. Sales taxes and value added taxes collected concurrently with revenue generating activities are excluded from revenue.

***Performance Obligations***

Substantially all of the Company's revenue is recognized at a point in time, upon shipment, rather than over time.

At the request of its customers, the Company may perform professional services, generally for the maintenance and repair of products previously sold to those customers and for engineering services. Professional services are typically short in duration and aggregate to less than 3% of the Company's consolidated revenue. Revenue is typically recognized at a point in time when control transfers to the customer upon completion of professional services. These services generally involve a single distinct performance obligation. The consideration expected to be received in exchange for such services is normally the contractually stated amount.

The Company occasionally sells separately priced non-standard/extended warranty services or preventative maintenance plans with the sale of products. The transfer of control over the service plans is over time. The Company recognizes the related revenue ratably over the terms of the service plans. The transaction price of a contract is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are generally determined based on the prices charged to customers or using the expected cost plus a margin.

***Shipping & Handling Costs***

The Company accounts for shipping and handling activities that occur after the transfer of control over the related goods as fulfillment activities rather than performance obligations. Shipping and handling fees charged to customers are recognized as revenue and the related costs are recorded in cost of revenue at the time of transfer of control.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

***Warranties***

The standard warranty periods for the Company's products are typically 12 months to 36 months. The Company recognizes estimated liabilities associated with standard warranty periods for its products in accordance with the provisions of ASC 450, "Contingencies," as the Company has the ability to ascertain the likelihood of the liabilities and can reasonably estimate the amount of the liabilities. A provision for the estimated cost related to standard warranties is recorded as cost of revenue at the time revenue is recognized. The Company's estimate of the costs to service the warranty obligations is based on historical experience and expectations of future conditions. To the extent that the Company's experience in warranty claims or costs associated with servicing those claims differ from the original estimates, revisions to the estimated warranty liabilities are recorded at that time, with offsetting adjustments to cost of revenue.

***Practical Expedients and Exemptions***

The Company expenses incremental direct costs of obtaining a contract when incurred because the expected amortization period is typically one year or less. These costs are recorded within selling, general and administrative expenses in the consolidated statement of operations.

The Company does not adjust the promised amount of consideration for the effects of a financing component because the transfer of a promised good to a customer and the customer's payment for that good are typically one year or less. The Company does not disclose the value of the remaining performance obligation for contracts with an original expected length of one year or less.

***Contract Liabilities***

Contract liabilities consist of deferred revenue and advance payments from customers, including amounts that are refundable. These contract liabilities are classified as either current or long-term liabilities in the consolidated balance sheet based on the timing of when the Company expects to recognize the related revenue. As of June 27, 2025 and December 31, 2024, contract liabilities were \$7.1 million and \$5.9 million, respectively, and are included in accrued expenses and other current liabilities and other liabilities in the accompanying consolidated balance sheets. The increase in the contract liability balance during the six months ended June 27, 2025 is primarily due to cash payments received in advance of satisfying performance obligations, partially offset by \$2.6 million of revenue recognized during the period that was included in the contract liability balance as of December 31, 2024.

***Disaggregated Revenue***

See Note 16 for the Company's disaggregation of revenue by segment, geography and end market. The following table presents revenues disaggregated by the capabilities of the underlying products and technologies during the three and six months ended June 27, 2025 and June 28, 2024, respectively (in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Precision Manufacturing	\$ 43,837	\$ 49,343	\$ 88,416	\$ 103,502
Robotics and Automation	77,835	67,386	156,423	130,616
Automation Enabling Technologies	121,672	116,729	244,839	234,118
Precision Medicine	59,161	67,710	113,173	132,311
Advanced Surgery	60,216	51,425	116,403	100,351
Medical Solutions	119,377	119,135	229,576	232,662
Total Revenue	<u>\$ 241,049</u>	<u>\$ 235,864</u>	<u>\$ 474,415</u>	<u>\$ 466,780</u>

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

**3. Business Combinations**

On April 8, 2025, the Company acquired 100% of the outstanding stock of Keonn Technologies, S.L. (“Keonn”) pursuant to the terms of a Share Purchase Agreement. At the closing date, Keonn became a wholly-owned subsidiary of the Company. Keonn is a manufacturer of Radio-Frequency Identification (“RFID”) solutions, based in Barcelona, Spain.

The acquisition of Keonn has been accounted for as a business combination under ASC 805, *Business Combinations* (“ASC 805”). Under ASC 805, assets acquired and liabilities assumed in a business combination are recorded at their fair value as of the acquisition date. The Company’s consolidated financial statements include results of operations for Keonn from the April 8, 2025 acquisition date.

***Consideration Transferred***

Pursuant to the Share Purchase Agreement, the Company acquired all outstanding equity of Keonn for estimated total purchase consideration of \$75.4 million, which consists of:

Cash consideration	\$	67,218
Deferred consideration		3,674
Estimated fair value of contingent consideration		4,537
Estimated total purchase consideration	\$	<u>75,429</u>

Contingent consideration represents additional payments that the Company may be required to make in the future, between €0 and €20.0 million (approximately \$21.9 million as of the acquisition date), depending on the achievement of specified revenue targets by Keonn during fiscal years 2025 through 2027, as well as maintaining certain minimum gross margin targets during the applicable periods. The fair value of the contingent consideration was determined based on a Monte Carlo simulation model in an option pricing framework at the acquisition date, whereby a range of possible scenarios were simulated. Refer to Note 6 for additional information on the valuation assumptions utilized in the Monte Carlo simulation. Deferred consideration is related to a purchase price holdback and customary closing and net working capital adjustments which will be resolved within four years of the acquisition date. The liabilities for contingent and deferred consideration are included in other current and long-term liabilities on the consolidated balance sheets, based on their respective settlement dates. These liabilities are remeasured at the end of each reporting period until related contingencies are resolved.

***Allocation of Purchase Price***

The purchase price is allocated based upon a valuation of the fair values of assets acquired and liabilities assumed. Assets acquired and liabilities assumed have been recorded at their estimated fair values as of the acquisition date. The excess of the purchase price over the fair values of the acquired tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. The fair values of identifiable intangible assets were based on valuations using an income approach, specifically the multi-period excess earnings method for customer relationships and the relief-from-royalty method for developed technologies and trade name. The process for estimating the fair values of identifiable intangible assets requires the use of significant estimates and assumptions, including revenue growth rates, customer attrition rates, royalty rates, discount rates, technology obsolescence curves, and EBITDA margins. The Company’s estimates and assumptions in determining the estimated fair value of certain assets and liabilities are subject to change within the measurement period (up to one year from the acquisition date) as a result of additional information to be obtained with regard to facts and circumstances that existed as of the acquisition date.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

Based upon the Company's preliminary valuation, the purchase price for Keonn was allocated as follows (in thousands):

	<b>Purchase Price Allocation</b>
Cash	\$ 4,045
Accounts receivable	1,977
Inventory	5,377
Property, plant and equipment	1,401
Operating lease assets	3,124
Intangible assets	32,326
Goodwill	44,214
Other assets	1,412
<b>Total assets acquired</b>	<b>93,876</b>
Accounts payable	1,593
Operating lease liabilities	3,124
Debt	2,504
Deferred tax liabilities	7,150
Other liabilities	4,076
<b>Total liabilities assumed</b>	<b>18,447</b>
Total assets acquired, net of liabilities assumed	75,429
Less: cash acquired	4,045
Purchase price, net of cash acquired	<u>\$ 71,384</u>

The fair value of intangible assets for Keonn is comprised of the following:

	<b>Estimated Fair Value (In thousands)</b>	<b>Amortization Period</b>
Developed technologies	\$ 9,753	9 years
Customer relationships	21,477	9 years
Trade name	1,096	14 years
Total	<u>\$ 32,326</u>	

The preliminary purchase price allocation resulted in \$32.3 million of identifiable intangible assets and \$44.2 million of goodwill. As the Keonn acquisition was structured as a stock acquisition for income tax purposes, the goodwill is not deductible. The goodwill recorded represents the anticipated incremental value of future cash flows potentially attributable to: (i) Keonn's ability to grow the business with existing and new customers, including leveraging the Company's customer base; (ii) Keonn's ability to grow the business through new product introductions; and (iii) cost improvements due to the integration of Keonn's operations into the Company's existing infrastructure.

The operating results of Keonn were included in the Company's results of operations beginning on April 8, 2025. Keonn contributed revenues of \$6.2 million and a loss before income taxes of \$0.7 million to the Company's operating results for the six months ended June 27, 2025. The loss before income taxes from Keonn for the period from the acquisition date through June 27, 2025 included amortization of purchased intangible assets of \$1.8 million.

The pro forma financial information reflecting the operating results of Keonn, as if it had been acquired as of January 1, 2024, would not differ materially from the operating results of the Company as reported for the year ended December 31, 2024.

**Acquisition Costs**

Acquisition costs are expensed in the periods in which the costs are incurred and included in restructuring, acquisition and related costs in the consolidated statements of operations. Acquisition-related costs for Keonn were \$2.1 million for the six months ended June 27, 2025.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

**4. Accumulated Other Comprehensive Loss**

Changes in accumulated other comprehensive loss were as follows (in thousands):

	Total Accumulated Other Comprehensive Loss	Cumulative Translation Adjustments	Pension Liability Adjustments
Balance at December 31, 2024	\$ (29,921)	\$ (23,686)	\$ (6,235)
Other comprehensive income (loss)	28,380	28,957	(577)
Amounts reclassified from accumulated other comprehensive loss	409	—	409
Balance at June 27, 2025	<u>\$ (1,132)</u>	<u>\$ 5,271</u>	<u>\$ (6,403)</u>

The amounts reclassified from accumulated other comprehensive loss were included in other income (expense) in the consolidated statements of operations.

**5. Earnings per Common Share**

Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Fully vested restricted stock units and deferred stock units granted to members of the Company's Board of Directors are included in the calculation of weighted average number of common shares outstanding.

For diluted earnings per common share, the denominator includes the dilutive effect of outstanding common share equivalents. The dilutive effects of outstanding common share equivalents, including outstanding service-based restricted stock units, stock options and performance-based restricted stock units, are determined using the treasury stock method. Performance-based restricted stock units are considered contingently issuable shares, the vesting of which may be based on achievement of specified company financial performance metrics ("attainment-based PSUs"), certain market conditions ("market-based PSUs") or a hybrid of company financial performance metrics and market conditions ("hybrid PSUs"). The dilutive effects of market-based PSUs are included in the weighted average common share calculation based on the number of shares, if any, that would be issuable as of the end of the reporting period, assuming the end of the reporting period is also the end of the performance period. The dilutive effects of attainment-based and hybrid PSUs are included in the weighted average common share calculation based on the cumulative achievement against the performance targets only when the performance targets have been achieved as of the end of the reporting period.

The following table sets forth the computation of basic and diluted earnings per common share (amounts in thousands, except per share data):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
<b>Numerators:</b>				
Net income	<u>\$ 4,497</u>	<u>\$ 13,755</u>	<u>\$ 25,705</u>	<u>\$ 28,431</u>
<b>Denominators:</b>				
Weighted average common shares outstanding— basic	36,022	35,946	36,023	35,930
Dilutive common share equivalents	54	146	80	180
Weighted average common shares outstanding— diluted	<u>36,076</u>	<u>36,092</u>	<u>36,103</u>	<u>36,110</u>
Antidilutive common share equivalents excluded from above	344	166	260	119
<b>Earnings per Common Share:</b>				
Basic	\$ 0.12	\$ 0.38	\$ 0.71	\$ 0.79
Diluted	\$ 0.12	\$ 0.38	\$ 0.71	\$ 0.79

For the three and six months ended June 27, 2025, 291 thousand shares of attainment-based PSUs and hybrid PSUs were excluded from the calculation of the denominator because they were considered contingently issuable shares and the related performance targets had not been achieved as of June 27, 2025.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

For the three and six months ended June 28, 2024, 177 thousand shares of attainment-based PSUs and hybrid PSUs were excluded from the calculation of the denominator because they were considered contingently issuable shares and the related performance targets had not been achieved as of June 28, 2024.

**6. Fair Value Measurements**

ASC 820, "Fair Value Measurements," establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the third is considered unobservable:

- Level 1: Quoted prices for identical assets or liabilities in active markets which the Company can access
- Level 2: Observable inputs other than those described in Level 1
- Level 3: Unobservable inputs

***Current Assets and Liabilities***

The Company's cash equivalents are highly liquid investments with original maturities of three months or less, which represent assets measured at fair value on a recurring basis. The Company determines the fair value of cash equivalents using a market approach based on quoted prices in active markets. The fair values of cash equivalents, accounts receivable, income taxes receivable, accounts payable, income taxes payable and accrued expenses and other current liabilities approximate their carrying values because of their short-term nature.

***Foreign Currency Contracts***

The Company addresses market risks from changes in foreign currency exchange rates through a risk management program that includes the use of derivative financial instruments to mitigate certain balance sheet foreign currency transaction exposures. The Company uses foreign currency forward contracts as a part of its strategy to manage exposures related to foreign currency denominated monetary assets and liabilities. The fair value of these foreign currency forward contracts is reported either in other current assets or in other current liabilities as of the end of the reporting period.

***Contingent Considerations***

On April 8, 2025, the Company completed the acquisition of Keonn. Pursuant to the purchase and sale agreement, the former shareholders of Keonn (the "Sellers") are eligible to receive contingent consideration based on the achievement of specified revenue targets by Keonn during fiscal years 2025 through 2027. Payment of this contingent consideration is also subject to Keonn maintaining certain minimum gross margin percentage during the applicable periods. The undiscounted range of potential contingent consideration is between €0 and €20.0 million (approximately \$21.9 million). If the performance conditions are met, the contingent consideration will be payable annually, with the first payment due in the second quarter of 2026. As of the acquisition date, the estimated fair value of the contingent consideration was €4.1 million (approximately \$4.5 million), determined using the Monte Carlo valuation method. This amount was recorded as part of the purchase price. Subsequent changes in the estimated fair value are recognized in the consolidated statement of operations in restructuring, acquisition, and related costs until the liability is fully settled. There have been no changes in the fair value of the contingent consideration since the acquisition date.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

**Summary by Fair Value Hierarchy**

The following table summarizes the fair values of the Company's assets and liabilities measured at fair value on a recurring basis as of June 27, 2025 (in thousands):

	Fair Value	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)
<b>Assets</b>				
Prepaid expenses and other current assets:				
Foreign currency forward contracts	\$ 200	\$ —	\$ 200	\$ —
	<u>\$ 200</u>	<u>\$ —</u>	<u>\$ 200</u>	<u>\$ —</u>
<b>Liabilities</b>				
Accrued expenses and other current liabilities:				
Contingent considerations - Current	\$ 4,461	\$ —	\$ —	\$ 4,461
Contingent considerations - Long term	458	—	—	458
Foreign currency forward contracts	302	—	302	—
	<u>\$ 5,221</u>	<u>\$ —</u>	<u>\$ 302</u>	<u>\$ 4,919</u>

The following table summarizes the fair values of the Company's assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 (in thousands):

	Fair Value	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)
<b>Assets</b>				
Prepaid expenses and other current assets:				
Foreign currency forward contracts	\$ 1,226	\$ —	\$ 1,226	\$ —
	<u>\$ 1,226</u>	<u>\$ —</u>	<u>\$ 1,226</u>	<u>\$ —</u>
<b>Liabilities</b>				
Accrued expenses and other current liabilities:				
Contingent considerations - Current	\$ 57	\$ —	\$ —	\$ 57
Foreign currency forward contracts	1,401	—	1,401	—
	<u>\$ 1,458</u>	<u>\$ —</u>	<u>\$ 1,401</u>	<u>\$ 57</u>

Changes in the fair value of Level 3 contingent considerations during the six months ended June 27, 2025 were as follows (in thousands):

	Amount
Balance at December 31, 2024	\$ 57
Acquisition of Keonn	4,537
Payments	—
Fair value adjustments	—
Effect of foreign exchange rates	325
Balance at June 27, 2025	<u>\$ 4,919</u>

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

The following table provides qualitative information associated with the fair value measurement of the Company's Level 3 liabilities:

<u>Liability</u>	<u>June 27, 2025 Fair Value (in thousands)</u>	<u>Valuation Technique</u>	<u>Unobservable Inputs</u>	<u>Percentage Applied</u>
Contingent consideration (Keonn)	\$4,856	Monte Carlo method	Historical and projected revenue from fiscal year 2025 to 2027	N/A
			Gross Profit Premium	8.8%
			Revenue risk premium	8.0%
			Gross Profit Volatility	44.0%
			Revenue Volatility	40.0%
Credit spread	3.6%			

See Note 10 to Consolidated Financial Statements for a discussion of the estimated fair value of the Company's outstanding debt.

### 7. Foreign Currency Contracts

The Company addresses market risks from changes in foreign currency exchange rates through a risk management program that includes the use of derivative financial instruments to mitigate certain foreign currency transaction exposures from future settlement of non-functional currency monetary assets and liabilities as of the end of a period. The Company does not enter into derivative transactions for speculative purposes. Gains and losses on these derivative financial instruments substantially offset losses and gains on the underlying hedged exposures and are included in foreign exchange transaction gains (losses) in the consolidated statements of operations. Furthermore, the Company manages its exposures to counterparty risks on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.

As of June 27, 2025, the aggregate notional amount and fair value of the Company's foreign currency forward contracts was \$54.4 million and a net loss of \$0.1 million, respectively. As of December 31, 2024, the aggregate notional amount and fair value of the Company's foreign currency forward contracts was \$187.4 million and a net loss of \$0.2 million, respectively.

The Company recognized an aggregate net loss of \$2.1 million and \$1.8 million for the three and six months ended June 27, 2025 and an aggregate net gain of \$1.0 million and \$2.2 million for the three and six months ended June 28, 2024. These amounts were included in foreign exchange transaction gains (losses) in the consolidated statements of operations.

### 8. Goodwill and Intangible Assets

#### *Goodwill*

Goodwill is recorded when the consideration paid for a business combination exceeds the fair value of net tangible and identifiable intangible assets acquired. The Company tests its goodwill balances for impairment annually as of the beginning of the second quarter or more frequently if indicators are present or changes in circumstances suggest that an impairment may exist. The Company performed the most recent annual goodwill and indefinite-lived intangible asset impairment test as of the beginning of the second quarter of 2025 and noted no impairment.

The following table summarizes changes in goodwill during the six months ended June 27, 2025 (in thousands):

	<u>Amount</u>
Balance at beginning of the period	\$ 584,098
Goodwill acquired from Keonn acquisition	44,214
Effect of foreign exchange rate changes	20,781
Balance at end of the period	<u>\$ 649,093</u>

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

Goodwill by reportable segment as of June 27, 2025 was as follows (in thousands):

	Reportable Segment		Total
	Automation Enabling Technologies	Medical Solutions	
Goodwill	\$ 447,763	\$ 352,559	\$ 800,322
Accumulated impairment of goodwill	(119,507)	(31,722)	(151,229)
<b>Total</b>	<b>\$ 328,256</b>	<b>\$ 320,837</b>	<b>\$ 649,093</b>

Goodwill by reportable segment as of December 31, 2024 was as follows (in thousands):

	Reportable Segment		Total
	Automation Enabling Technologies	Medical Solutions	
Goodwill	\$ 439,980	\$ 295,347	\$ 735,327
Accumulated impairment of goodwill	(119,507)	(31,722)	(151,229)
<b>Total</b>	<b>\$ 320,473</b>	<b>\$ 263,625</b>	<b>\$ 584,098</b>

**Intangible Assets**

Intangible assets as of June 27, 2025 and December 31, 2024, respectively, are summarized as follows (in thousands):

	June 27, 2025			December 31, 2024		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
<b>Amortizable intangible assets:</b>						
Patents and developed technologies	\$ 236,374	\$ (172,760)	\$ 63,614	\$ 218,867	\$ (159,041)	\$ 59,826
Customer relationships	296,698	(177,267)	119,431	265,156	(158,938)	106,218
Trademarks and trade names	25,352	(17,794)	7,558	23,367	(16,594)	6,773
<b>Amortizable intangible assets</b>	<b>558,424</b>	<b>(367,821)</b>	<b>190,603</b>	<b>507,390</b>	<b>(334,573)</b>	<b>172,817</b>
<b>Non-amortizable intangible assets:</b>						
Trade names	13,027	—	13,027	13,027	—	13,027
<b>Total intangible assets</b>	<b>\$ 571,451</b>	<b>\$ (367,821)</b>	<b>\$ 203,630</b>	<b>\$ 520,417</b>	<b>\$ (334,573)</b>	<b>\$ 185,844</b>

All definite-lived intangible assets are amortized either on a straight-line basis or an economic benefit basis over their remaining estimated useful life. Amortization expense for patents and developed technologies is included in cost of revenue in the accompanying consolidated statements of operations. Amortization expense for customer relationships and definite-lived trademarks, trade names and other intangibles is included in operating expenses in the accompanying consolidated statements of operations. Amortization expense was as follows (in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Amortization expense – cost of revenue	\$ 4,220	\$ 3,685	\$ 7,781	\$ 7,377
Amortization expense – operating expenses	6,871	6,907	12,425	12,657
<b>Total amortization expense</b>	<b>\$ 11,091</b>	<b>\$ 10,592</b>	<b>\$ 20,206</b>	<b>\$ 20,034</b>

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

As of June 27, 2025, estimated amortization expense for each of the five succeeding years and thereafter was as follows (in thousands):

Year Ending December 31,	Cost of Revenue	Operating Expenses	Total
2025 (remainder of year)	\$ 8,517	\$ 13,889	\$ 22,406
2026	15,057	23,003	38,060
2027	12,128	19,131	31,259
2028	10,318	16,076	26,394
2029	7,446	12,455	19,901
Thereafter	10,148	42,435	52,583
<b>Total</b>	<b>\$ 63,614</b>	<b>\$ 126,989</b>	<b>\$ 190,603</b>

**9. Supplementary Balance Sheet Information**

The following tables provide the details of selected balance sheet items as of the periods indicated (in thousands):

***Inventories***

	June 27, 2025	December 31, 2024
Raw materials	\$ 109,415	\$ 92,198
Work-in-process	26,005	24,719
Finished goods	31,997	27,327
Demo and consigned inventory	648	362
<b>Total inventories</b>	<b>\$ 168,065</b>	<b>\$ 144,606</b>

***Accrued Expenses and Other Current Liabilities***

	June 27, 2025	December 31, 2024
Accrued compensation and benefits	\$ 17,261	\$ 28,361
Accrued warranty	4,809	4,805
Contract liabilities, current portion	6,906	5,715
Accrued restructuring	13,477	6,131
Accrued earn-outs and contingent considerations	4,461	57
Other	17,609	15,262
<b>Total</b>	<b>\$ 64,523</b>	<b>\$ 60,331</b>

***Accrued Warranty***

	Six Months Ended	
	June 27, 2025	June 28, 2024
Balance at beginning of the period	\$ 4,805	\$ 5,292
Provision charged to cost of revenue	1,151	595
Warranty liabilities acquired from acquisitions	—	76
Use of provision	(1,249)	(913)
Foreign currency exchange rate changes	102	(11)
<b>Balance at end of the period</b>	<b>\$ 4,809</b>	<b>\$ 5,039</b>

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

***Other Long-Term Liabilities***

	June 27, 2025	December 31, 2024
Finance lease obligations	\$ 2,779	\$ 3,175
Other	4,036	1,316
<b>Total</b>	<b>\$ 6,815</b>	<b>\$ 4,491</b>

**10. Debt**

Outstanding debt consisted of the following (in thousands):

	June 27, 2025	December 31, 2024
Senior Credit Facilities – term loans	\$ 5,300	\$ 4,710
Less: unamortized debt issuance costs	(97)	(19)
<b>Total current portion of long-term debt</b>	<b>\$ 5,203</b>	<b>\$ 4,691</b>
Senior Credit Facilities – term loans	\$ 146,283	\$ 65,698
Senior Credit Facilities – revolving credit facility	313,495	348,751
Less: unamortized debt issuance costs	(5,741)	(2,500)
<b>Total long-term debt</b>	<b>\$ 454,037</b>	<b>\$ 411,949</b>
<b>Total Senior Credit Facilities</b>	<b>\$ 459,240</b>	<b>\$ 416,640</b>

***Senior Credit Facilities***

On June 27, 2025, the Company entered into an amended and restated credit agreement (the “Fourth Amended and Restated Credit Agreement”) with existing and new lenders for an aggregate credit facility of approximately \$1.0 billion, consisting of a €65.3 million euro-denominated 5-year term loan facility (the “Euro Term Loans”), a \$75.0 million U.S. Dollar denominated 5-year term loan facility (the “U.S. Term Loans” and together with the Euro Term Loans, the “Term Loans”), and an \$850.0 million 5-year revolving credit facility (the “Revolving Facility”, and together with the Euro Term Loans and the U.S. Term Loans, collectively, the “Senior Credit Facilities”). The Senior Credit Facilities mature in June 2030 and include an uncommitted “accordion” feature pursuant to which the commitments thereunder may be increased by an additional \$350.0 million in aggregate, subject to the satisfaction of certain customary conditions. In connection with the Fourth Amended and Restated Credit Agreement, the Company capitalized \$4.3 million deferred financing costs and recorded a \$0.4 million loss from the write-off of a portion of the unamortized deferred financing costs.

The outstanding principal balance under the Euro Term Loans is payable in quarterly installments of €1.1 million (approximately \$1.3 million), beginning in September 2025, with the remaining balance due upon maturity. The U.S. Term Loans requires quarterly installments of \$0.5 million starting in September 2026, increasing to \$0.9 million beginning in September 2027, with the remaining balance also due upon maturity. The Company may make additional principal payments at any time, which will reduce the next scheduled installment. Borrowings under the Revolving Facility may be repaid at any time prior to maturity. The Company made principal payments of €2.3 million (\$2.5 million) towards the Term Loans and \$38.5 million towards its Revolving Facility during the six months ended June 27, 2025.

The Company is required to satisfy certain financial and non-financial covenants under the Fourth Amended and Restated Credit Agreement. The Fourth Amended and Restated Credit Agreement also contains customary events of default. The Company was in compliance with these covenants as of June 27, 2025.

***Liens***

The Company’s obligations under the Senior Credit Facilities are secured, on a senior basis, by a lien on substantially all of the assets of Novanta Inc.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

***Fair Value of Debt***

As of June 27, 2025 and December 31, 2024, the outstanding balance of the Company's debt approximated its fair value based on current rates available to the Company for debt of similar maturities. The fair value of the Company's debt is classified as Level 2 under the fair value hierarchy.

**11. Leases**

Most leases held by the Company expire between 2025 and 2037. In the U.K., where longer lease terms are more common, the Company has a land lease that extends through 2078. Certain leases include one or more options to renew the lease terms from one to ten years and options to terminate the leases within one year. The exercise of lease renewal or termination options is at the Company's sole discretion; therefore, the majority of renewal options to extend the lease terms are not included in the Company's right-of-use assets and operating lease liabilities as they are not reasonably certain of being exercised. The Company regularly evaluates the renewal options and includes the renewal periods in the lease term when they are reasonably certain of being exercised. The depreciable lives of the right-of-use assets and leasehold improvements are limited to the expected lease terms.

The following table summarizes the components of lease costs (in thousands):

	<u>Three Months Ended</u>		<u>Six Months Ended</u>	
	<u>June 27, 2025</u>	<u>June 28, 2024</u>	<u>June 27, 2025</u>	<u>June 28, 2024</u>
Operating lease cost	\$ 2,881	\$ 2,834	\$ 5,620	\$ 5,801
Finance lease cost				
Amortization of right-of-use assets	150	150	301	301
Interest on lease liabilities	50	60	102	122
Variable lease cost	394	342	670	593
Total lease cost	<u>\$ 3,475</u>	<u>\$ 3,386</u>	<u>\$ 6,693</u>	<u>\$ 6,817</u>

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

The following table provides additional details of balance sheet information related to the Company's leases (in thousands, except lease term and discount rate):

	<u>June 27, 2025</u>	<u>December 31, 2024</u>
<b>Operating leases</b>		
Operating lease right-of-use assets	\$ 44,107	\$ 42,908
Current portion of operating lease liabilities	\$ 10,302	\$ 9,879
Operating lease liabilities	41,086	40,548
Total operating lease liabilities	<u>\$ 51,388</u>	<u>\$ 50,427</u>
<b>Finance leases</b>		
Property, plant and equipment, gross	\$ 9,582	\$ 9,582
Accumulated depreciation	(7,175)	(6,874)
Finance lease assets included in property, plant and equipment, net	<u>\$ 2,407</u>	<u>\$ 2,708</u>
Accrued expenses and other current liabilities	\$ 780	\$ 759
Other liabilities	2,779	3,175
Total finance lease liabilities	<u>\$ 3,559</u>	<u>\$ 3,934</u>
<b>Weighted-average remaining lease term (in years):</b>		
Operating leases	7.5	7.4
Finance leases	4.0	4.5
<b>Weighted-average discount rate:</b>		
Operating leases	4.79%	4.82%
Finance leases	5.54%	5.54%

The following table provides additional details of cash flow information related to the Company's leases (in thousands):

	<u>Six Months Ended</u>	
	<u>June 27, 2025</u>	<u>June 28, 2024</u>
<b>Cash paid for lease liabilities:</b>		
Operating cash outflows related to finance leases	\$ 102	\$ 122
Operating cash outflows related to operating leases	\$ 5,019	\$ 4,314
Financing cash outflows related to finance leases	\$ 375	\$ 355
<b>Supplemental non-cash information:</b>		
Right-of-use assets obtained in exchange for new operating lease liabilities <sup>(1)</sup>	\$ 3,602	\$ 9,623

<sup>(1)</sup> The amount for the six months ended June 27, 2025 includes \$3.1 million of right-of-use assets acquired as part of the Keonn acquisition. The amount for the six months ended June 28, 2024 includes \$8.1 million of right-of-use assets acquired as part of the Motion Solutions Parent Corp. acquisition.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

Future minimum lease payments under operating and finance leases expiring subsequent to June 27, 2025, including operating leases associated with facilities that have been vacated as a result of the Company's restructuring actions, are summarized as follows (in thousands):

Year Ending December 31,	Operating Leases		Finance Leases	
2025 (remainder of year)	\$	6,201	\$	477
2026		11,324		979
2027		9,765		1,003
2028		6,731		1,003
2029		5,852		502
Thereafter		22,932		—
Total minimum lease payments		62,805		3,964
Less: Interest		(11,417)		(405)
Present value of lease liabilities	\$	51,388	\$	3,559

## 12. Preferred and Common Shares and Share-Based Compensation

### *Preferred Shares*

In May 2021, the Company's shareholders approved a special resolution to amend the Company's articles to authorize up to 7.0 million preferred shares for future issuance. The Company's Board of Directors is authorized to designate and issue one or more series of preferred shares, fix the rights, preferences and designation, as deemed necessary or advisable, relating to the preferred shares, provided that no shares of any series may be entitled to more than one vote per share. As of June 27, 2025, no preferred shares had been issued and outstanding.

### *Common Share Repurchases*

In February 2020, the Company's Board of Directors approved a share repurchase plan (the "2020 Repurchase Plan"), authorizing the repurchase of \$50.0 million worth of the Company's common shares. During the six months ended June 27, 2025, the Company repurchased 46 thousand shares under the 2020 Repurchase Plan for an aggregate purchase price of \$6.2 million and an average price of \$134.54 per share. As of June 27, 2025, the Company had \$43.3 million available for future share repurchases under the 2020 Repurchase Plan.

### *Share-Based Compensation Expense*

The table below summarizes share-based compensation expense recorded in the consolidated statements of operations (in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Selling, general and administrative	\$ 6,390	\$ 5,552	\$ 12,526	\$ 10,649
Research and development and engineering	649	601	1,264	1,160
Cost of revenue	459	78	808	499
Total share-based compensation expense	\$ 7,498	\$ 6,231	\$ 14,598	\$ 12,308

Share-based compensation expense reported in selling, general and administrative expenses included expenses related to restricted stock units granted to the members of the Company's Board of Directors of \$1.6 million and \$1.5 million during the six months ended June 27, 2025 and June 28, 2024, respectively.

### *Restricted Stock Units*

The Company's restricted stock units ("RSUs") have generally been issued with vesting periods ranging from zero to four years and vest based solely on service conditions. Accordingly, the Company recognizes compensation expense on a straight-line

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

basis over the requisite service period. The Company reduces the compensation expense by an estimated forfeiture rate which is based on anticipated forfeitures and historical forfeiture experience.

The table below summarizes activities relating to RSUs issued and outstanding under the Company's Amended and Restated 2010 Incentive Plan during the six months ended June 27, 2025:

	Shares (In thousands)	Weighted Average Grant Date Fair Value
Unvested at December 31, 2024	198	\$ 154.43
Granted	299	\$ 131.05
Vested	(83)	\$ 148.01
Forfeited	(17)	\$ 154.08
Unvested at June 27, 2025	397	\$ 138.18
Expected to vest as of June 27, 2025	357	

The total fair value of RSUs that vested during the six months ended June 27, 2025 was \$11.5 million based on the market price of the underlying shares on the date of vesting.

***Performance Stock Units***

The Company typically grants PSUs that are based on the Company's financial performance metrics, market conditions, or a hybrid of company financial performance metrics and market conditions. These PSUs generally cliff vest on the first day following the end of the specified performance period.

The number of common shares to be issued upon settlement following vesting of attainment-based PSUs is determined based on the Company's financial performance metrics over the specified performance period against the targets established by the Company's Board of Directors at the time of grant and will be in the range of zero to 200% of the target number of shares. The Company recognizes the related compensation expense ratably over the performance period based on the number of shares that are deemed probable of vesting at the end of the specified performance period. This probability assessment is performed quarterly and the cumulative effect of a change in the estimated compensation expense, if any, is recognized in the consolidated statement of operations in the period in which such determination is made.

The number of common shares to be issued upon settlement following vesting of market-based PSUs is determined based on the relative market performance of the Company's common shares compared to the Russell 2000 Index over the specified performance period using a payout formula established by the Company's Board of Directors at the time of grant and will be in the range of zero to 200% of the target number of shares. The Company recognizes the related compensation expense based on the fair value of the market-based PSUs, determined using the Monte-Carlo valuation method as of the grant date, on a straight-line basis from the grant date to the end of the specified performance period. Compensation expense on market-based PSUs will not be affected by the number of shares that will ultimately vest at the end of the specified performance period.

The number of common shares to be issued upon settlement following vesting of PSU awards that are based on the achievement of a hybrid of company financial performance metrics and market conditions ("Hybrid PSUs") is determined based on the Company's financial performance metrics achieved over the specified performance period against the targets established by the Company's Board of Directors at the time of grant and a market-based multiplier based on the percentile ranking of the relative market performance of the Company's common shares compared to the Russell 2000 Index companies. The payout will be in the range of zero to 260% of the target number of shares. The Company determines the fair value of these Hybrid PSUs using the Monte-Carlo valuation method as of the grant date. The Company recognizes compensation expense associated with the Hybrid PSUs ratably over the performance period based on the fair value of the PSUs as of the grant date and the number of shares that are deemed probable of vesting based on the estimated achievement of the pertinent company financial performance metrics at the end of the specified performance period. The probability assessment is performed quarterly and the cumulative effect of a change in the estimated compensation expense, if any, is recognized in the consolidated statement of operations in the period in which such determination is made.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

The table below summarizes the activities relating to the performance-based awards issued and outstanding under the Company's Amended and Restated 2010 Incentive Plan during the six months ended June 27, 2025:

	Shares (In thousands)	Weighted Average Grant- Date Fair Value
Unvested at December 31, 2024	227	\$ 165.13
Granted	157	\$ 133.11
Performance adjustments <sup>(1)</sup>	(7)	\$ 140.62
Vested	(49)	\$ 139.41
Forfeited	(14)	\$ 167.02
Unvested at June 27, 2025	314	\$ 153.67
Expected to vest as of June 27, 2025	260	

<sup>(1)</sup> The amount shown represents performance adjustments related to the performance-based awards vested during the six months ended June 27, 2025.

The unvested PSUs are shown at target payout levels in the table above. As of June 27, 2025, the maximum number of common shares that could be earned under these PSU grants was approximately 617 thousand shares.

The total fair value of PSUs that vested during the six months ended June 27, 2025 was \$7.2 million based on the market price of the underlying common shares on the date of vesting.

The grant-date fair value per unit of the hybrid PSUs granted during the six months ended June 27, 2025 was estimated using the Monte Carlo valuation method with the following assumptions:

	Six Months Ended June 27, 2025	
Grant-date stock price	\$	142.80
Expected volatility		36.94%
Risk-free interest rate		4.18%
Expected annual dividend yield		—
Fair value	\$	160.93

**Stock Options**

The table below summarizes the activities relating to stock options issued and outstanding under the Company's Amended and Restated 2010 Incentive Plan during the six months ended June 27, 2025:

	Shares (In thousands)	Weighted Average Exercise Price
Outstanding as of December 31, 2024	149	\$ 139.17
Granted	—	\$ —
Exercised	(4)	\$ 135.86
Forfeited or expired	(4)	\$ 156.91
Outstanding as of June 27, 2025	141	\$ 138.77
Exercisable as of June 27, 2025	94	
Expected to vest as of June 27, 2025	47	

**13. Income Taxes**

The Company determines its estimated annual effective tax rate at the end of each interim period based on full year forecasted pre-tax income and facts known at that time. The estimated annual effective tax rate is applied to the year-to-date pre-tax income at the end of each interim period with the cumulative effect of any changes in the estimated annual effective tax rate being recorded in

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

the period in which the changes are determined. The tax effect of significant unusual items is reflected in the period in which they occur. Since the Company is incorporated in Canada, it is required to use Canada's statutory tax rate of 29.0% in the determination of the estimated annual effective tax rate.

The Company maintains a valuation allowance on balances of certain U.S. state net operating losses, credits and certain non-U.S. tax attributes that the Company has determined are not more likely than not to be realized. A valuation allowance is required when, based upon an assessment of various factors, including recent operating loss history, anticipated future earnings, and prudent and reasonable tax planning strategies, it is more likely than not that some portion of the deferred tax assets will not be realized. In conjunction with the Company's ongoing review of its actual results and anticipated future earnings, the Company continuously reassesses the possibility of adding a new or additional valuation allowance or releasing the valuation allowance currently in place on its deferred tax assets.

The Company's effective tax rate of 22.3% for the three months ended June 27, 2025 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated U.S. tax benefits for Foreign Derived Intangible Income ("FDII") and R&D tax credits, and U.K. patent box deductions; partially offset by various non-deductible transaction-related and compensation expenses and uncertain tax position accruals.

The Company's effective tax rate of 20.2% for the six months ended June 27, 2025 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated U.S. tax benefits for Foreign Derived Intangible Income ("FDII") and R&D tax credits, and U.K. patent box deductions; partially offset by various non-deductible transaction-related and compensation expenses and uncertain tax position accruals.

The Company's effective tax rate of 19.7% for the three months ended June 28, 2024 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions and R&D tax credits, partially offset by disallowed compensation deductions, uncertain tax position accruals, and Pillar Two inclusion.

The Company's effective tax rate of 16.5% for the six months ended June 28, 2024 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions, R&D tax credits, and windfall tax benefits upon vesting of certain share-based compensation awards, partially offset by disallowed compensation deductions, uncertain tax position accruals, and Pillar Two inclusion. For the six months ended June 28, 2024, the tax benefits upon vesting of certain share-based compensation awards had a benefit of 3.5% on the Company's effective tax rate.

On July 4, 2025, the U.S. enacted H.R.1 - One Big Beautiful Bill Act (the "Act"). The Act contains numerous income tax provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act and modifications to the international tax framework. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The Company is currently assessing its impact on our consolidated financial statements.

#### 14. Restructuring, Acquisition, and Related Costs

The following table summarizes restructuring, acquisition, and related costs in the accompanying consolidated statements of operations (in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
2025 restructuring	\$ 6,836	\$ —	\$ 6,836	\$ —
2024 restructuring	3,385	2,523	3,975	3,071
2020 restructuring	—	—	(3,595)	—
Total restructuring charges	10,221	2,523	7,216	3,071
Acquisition and related charges	2,351	20	2,901	1,755
Total restructuring, acquisition, and related costs	\$ 12,572	\$ 2,543	\$ 10,117	\$ 4,826

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

**2025 Restructuring**

The Company initiated the 2025 restructuring program in the second quarter of 2025 in order to streamline operations and align with our long-term goals. The 2025 restructuring program includes measures to regionalize manufacturing operations, expedite the closure of certain sites, streamline management structures, and implement cost-saving strategies in areas anticipated to have a minimal long-term impact on the Company's overall business performance. During both the three and six months ended June 27, 2025, the Company recorded \$6.8 million in severance, facility related and other charges in connection with the 2025 restructuring program. As of June 27, 2025, the Company had incurred cumulative costs of \$6.8 million related to this restructuring program. The Company anticipates substantially completing the 2025 restructuring program by the end of 2026. Total restructuring charges related to this program are expected to range between \$20.0 million to \$25.0 million.

The following table summarizes restructuring costs associated with the 2025 restructuring program by reportable segment (in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Automation Enabling Technologies	\$ 940	\$ —	\$ 940	\$ —
Medical Solutions	4,202	—	4,202	—
Unallocated	1,694	—	1,694	—
<b>Total</b>	<b>\$ 6,836</b>	<b>\$ —</b>	<b>\$ 6,836</b>	<b>\$ —</b>

**2024 Restructuring**

As a result of the Company's acquisitions and ongoing integration activities, the Company initiated the 2024 restructuring program in the first quarter of 2024 in order to reduce operating complexity. During the three and six months ended June 27, 2025, the Company recorded \$3.4 million and \$4.0 million, respectively, in severance, facility related and other charges in connection with the 2024 restructuring program. As of June 27, 2025, the Company had incurred cumulative costs of \$14.5 million related to this restructuring program. The Company anticipates substantially completing the 2024 restructuring program by the end of 2025 and expects to incur additional restructuring charges of \$1.5 million to \$2.5 million related to the 2024 restructuring program.

The following table summarizes restructuring costs associated with the 2024 restructuring program by reportable segment (in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Automation Enabling Technologies	\$ 445	\$ 1,810	\$ 931	\$ 2,089
Medical Solutions	2,930	360	3,012	566
Unallocated	10	353	32	416
<b>Total</b>	<b>\$ 3,385</b>	<b>\$ 2,523</b>	<b>\$ 3,975</b>	<b>\$ 3,071</b>

**2020 Restructuring**

As a result of the Company's ongoing evaluations and efforts to reduce its operating costs, while improving efficiency and effectiveness, the Company initiated the 2020 restructuring program in the third quarter of 2020. This program was focused on reducing operating complexity in the Company, including reducing infrastructure costs and streamlining the Company's operating model to better serve its customers. In addition, the program was focused on cost reduction actions to improve gross margins for the overall company. As of June 27, 2025, the Company had incurred cumulative costs of \$13.1 million related to the 2020 restructuring program. The 2020 restructuring program activities were completed in the fourth quarter of 2023. In January 2025, the Company sold a facility from the 2020 restructuring program and recorded a \$3.6 million gain in the Company's Automation Enabling Technologies segment.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

***Roll-forward of Accrued Expenses Related to Restructuring***

The following table summarizes the accrual activities, by component, related to the Company's restructuring plans recorded in the accompanying consolidated balance sheets (in thousands):

	<u>Total</u>	<u>Employee Related</u>	<u>Facility Related</u>	<u>Facility Sale</u>	<u>Other</u>
Balance at December 31, 2024	\$ 6,751	\$ 5,690	\$ 1,061	\$ —	\$ —
Restructuring charges	7,216	9,191	1,503	(4,325)	847
Cash payments	1,849	(2,573)	(335)	5,537	(780)
Non-cash write-offs and other adjustments	(1,839)	719	(1,346)	(1,212)	—
Balance at June 27, 2025	<u>\$ 13,977</u>	<u>\$ 13,027</u>	<u>\$ 883</u>	<u>\$ —</u>	<u>\$ 67</u>

***Acquisition and Related Charges***

Acquisition costs in connection with business combinations, including advisor, legal, valuation, and other professional or consulting fees, totaled \$2.4 million and \$2.9 million for the three and six months ended June 27, 2025, and less than \$0.1 million and \$1.8 million for the three and six months ended June 28, 2024. The majority of acquisition and related costs for the three and six months ended June 27, 2025 and the three and six months ended June 28, 2024 were included in unallocated costs.

**15. Commitments and Contingencies**

***Purchase Commitments***

There have been no material changes to the Company's purchase commitments since December 31, 2024.

***Legal Contingencies***

The Company is subject to various legal proceedings and claims that arise in the ordinary course of business. The Company reviews the status of each significant matter and assesses the potential financial exposure on a quarterly basis. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available as of the date of the consolidated balance sheet. As additional information becomes available, the Company reassesses the potential liability related to any pending claims and litigation and may revise its estimates. When a material loss contingency is considered reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the potential loss or a range of potential losses, if such an estimate can be reasonably made. Legal fees are expensed as incurred. The Company does not believe that the outcome of outstanding claims will have a material adverse effect on its consolidated financial statements but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect on its consolidated financial statements.

***Guarantees and Indemnifications***

In the normal course of its operations, the Company executes agreements that provide for indemnification and guarantees to counterparties in transactions such as business dispositions, sale of assets, sale of products, and operating leases. Additionally, the by-laws of the Company require it to indemnify certain current or former directors, officers, and employees of the Company against expenses incurred by them in connection with each proceeding in which they are involved as a result of serving or having served in certain capacities. Indemnification is not available with respect to a proceeding as to which it has been adjudicated that the person did not act in good faith in the reasonable belief that the action was in the best interests of the Company. Certain of the Company's officers and directors are also a party to indemnification agreements with the Company. These indemnification agreements provide, among other things, that the director or officer shall be indemnified to the fullest extent permitted by applicable law against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such director or officer in connection with any proceeding by reason of their relationship with the Company. In addition, the indemnification agreements provide for the advancement of expenses incurred by such director or officer in connection with any proceeding covered by the indemnification agreement, subject to the conditions set forth therein and to the extent such advancement is not prohibited by law. The indemnification agreements also set out the procedures for determining entitlement to indemnification, the requirements relating to

NOVANTA INC.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  
AS OF JUNE 27, 2025  
(Unaudited)

notice and defense of claims for which indemnification is sought, the procedures for enforcement of indemnification rights, the limitations on and exclusions from indemnification, and the minimum levels of directors and officers liability insurance to be maintained by the Company.

## 16. Segment Information

### *Reportable Segments*

The Company's Chief Operating Decision Maker ("CODM") is the Chief Executive Officer. The CODM utilizes financial information to make decisions about allocating resources and assessing performance for the entire Company. The CODM evaluates the performance of, and allocates resources to, its segments based on revenue, gross profit and operating income. The Company's reportable segments have been identified based on commonality and adjacency of end markets and customers amongst the Company's individual product lines.

During the fourth quarter of 2024, the Company updated its organizational structure and re-aligned its financial reporting structure under two reportable segments: Automation Enabling Technologies and Medical Solutions. Prior to the reorganization, the Company's historical reportable segments were: Precision Medicine and Manufacturing, Robotics and Automation, and Medical Solutions. Prior period segment financial information has been recast to align with the new reportable segments herein, as well as in Notes 8 and 14.

### *Automation Enabling Technologies*

The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO<sub>2</sub> lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The segment serves highly demanding applications for advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures such as ophthalmology applications. The vast majority of the segment's product offerings are sold to OEM customers. The segment sells the majority of these products directly, utilizing a highly technical sales force, and also sells some indirectly, through resellers and distributors.

### *Medical Solutions*

The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio-frequency identification ("RFID") technologies, barcode identification technologies, thermal chart recorders, light and color measurement technologies, touch panel displays, and advanced motion control solutions. The vast majority of the segment's product offerings are sold to OEM customers. The segment sells the majority of these products directly, utilizing a highly technical sales force, and also sells some indirectly, through resellers and distributors.

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

**Reportable Segment Financial Information**

Results of operations, depreciation and amortization expenses by reportable segments for the periods indicated were as follows (in thousands):

	<u>Three Months Ended June 27, 2025</u>			<u>Six Months Ended June 27, 2025</u>		
	<u>Automation Enabling Technologies</u>	<u>Medical Solutions</u>	<u>Total</u>	<u>Automation Enabling Technologies</u>	<u>Medical Solutions</u>	<u>Total</u>
Revenue	\$ 121,672	\$ 119,377	\$ 241,049	\$ 244,839	\$ 229,576	\$ 474,415
Cost of revenue	62,136	66,973		124,559	129,009	
Amortization of purchased intangible assets	1,330	2,890		2,689	5,092	
Segment gross profit	58,206	49,514	107,720	117,591	95,475	213,066
Research and development and engineering	9,269	16,169		18,708	30,125	
Selling, general and administrative	18,331	15,064		37,489	29,794	
Amortization of purchased intangible assets	2,347	4,524		4,755	7,670	
Restructuring, acquisition, and related costs	1,385	7,132		(1,724)	7,232	
Segment operating income	26,874	6,625	33,499	58,363	20,654	79,017
Unallocated costs	—	—	(18,588)	—	—	(31,685)
Interest income (expense), net	—	—	(5,815)	—	—	(11,459)
Other income (expense), net	—	—	(3,307)	—	—	(3,666)
Income before income taxes	<u>\$ 26,874</u>	<u>\$ 6,625</u>	<u>\$ 5,789</u>	<u>\$ 58,363</u>	<u>\$ 20,654</u>	<u>\$ 32,207</u>

	<u>Three Months Ended June 28, 2024</u>			<u>Six Months Ended June 28, 2024</u>		
	<u>Automation Enabling Technologies</u>	<u>Medical Solutions</u>	<u>Total</u>	<u>Automation Enabling Technologies</u>	<u>Medical Solutions</u>	<u>Total</u>
Revenue	\$ 116,729	\$ 119,135	\$ 235,864	\$ 234,118	\$ 232,662	\$ 466,780
Cost of revenue	60,168	67,679		120,485	132,862	
Amortization of purchased intangible assets	1,566	2,119		3,136	4,241	
Segment gross profit	54,995	49,337	104,332	110,497	95,559	206,056
Research and development and engineering	9,977	13,901		19,974	27,167	
Selling, general and administrative	18,893	12,815		37,388	26,437	
Amortization of purchased intangible assets	2,796	4,111		5,597	7,060	
Restructuring, acquisition, and related costs	1,810	361		2,089	727	
Segment operating income	21,519	18,149	39,668	45,449	34,168	79,617
Unallocated costs	—	—	(13,953)	—	—	(28,295)
Interest income (expense), net	—	—	(8,266)	—	—	(16,520)
Other income (expense), net	—	—	(319)	—	—	(756)
Income before income taxes	<u>\$ 21,519</u>	<u>\$ 18,149</u>	<u>\$ 17,130</u>	<u>\$ 45,449</u>	<u>\$ 34,168</u>	<u>\$ 34,046</u>

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
<b>Depreciation and Amortization Expenses</b>				
Automation Enabling Technologies	\$ 5,445	\$ 5,869	\$ 10,921	\$ 11,725
Medical Solutions	9,745	7,813	17,424	14,410
Unallocated	391	434	799	910
<b>Total</b>	\$ 15,581	\$ 14,116	\$ 29,144	\$ 27,045

	June 27, 2025	December 31, 2024
<b>Accounts Receivable</b>		
Automation Enabling Technologies	\$ 66,164	\$ 70,829
Medical Solutions	95,038	80,197
Total accounts receivable	\$ 161,202	\$ 151,026
<b>Inventories</b>		
Automation Enabling Technologies	\$ 96,046	\$ 89,009
Medical Solutions	72,019	55,597
Total inventories	\$ 168,065	\$ 144,606
<b>Total segment assets</b>	\$ 329,267	\$ 295,632

**Revenue by Geography**

The Company aggregates geographic revenue based on the customer locations where products are shipped to. Revenue by geography was as follows (in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
United States	\$ 128,118	\$ 123,391	\$ 251,764	\$ 240,472
Germany	27,258	31,919	55,735	65,100
Rest of Europe	34,847	32,528	66,628	63,499
China	21,777	19,014	43,211	36,085
Rest of Asia-Pacific	24,667	25,334	48,046	52,590
Other	4,382	3,678	9,031	9,034
<b>Total</b>	\$ 241,049	\$ 235,864	\$ 474,415	\$ 466,780

The majority of revenue from the Automation Enabling Technologies and Medical Solutions segments are generated from sales to customers within the United States and Europe. Each segment also generates revenue across the other geographies, with no significant concentration of any segment's remaining revenue.

**Revenue by End Market**

The Company primarily operates in two end markets: the medical market and the advanced industrial market. Revenue by end market was approximately as follows:

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Medical	54%	58%	54%	57%
Advanced Industrial	46%	42%	46%	43%
<b>Total</b>	100%	100%	100%	100%

**NOVANTA INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**AS OF JUNE 27, 2025**  
**(Unaudited)**

The majority of the revenue from the Automation Enabling Technologies segment is generated from sales to customers in the advanced industrial market. The majority of the revenue from the Medical Solutions segment is generated from sales to customers in the medical market.

## Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

*Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the Consolidated Financial Statements and Notes included in Item 1 of this Quarterly Report on Form 10-Q. The MD&A contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. These forward-looking statements include, but are not limited to, our financial results and our financial condition; our belief that the Purchasing Managers Index (“PMI”) may provide an indication of the impact of general economic conditions on our sales into the advanced industrial end market; our strategy; anticipated financial performance; expected liquidity and capitalization; drivers of revenue growth and our growth expectations in various markets; management’s plans and objectives for future operations, expenditures and product development, and investments in research and development; business prospects; potential of future product releases and expansion of our product and service offerings; industry trends; market conditions; our competitive positions; changes in economic and political conditions, including supply chain disruptions and constraints and inflationary pressures; changes in accounting principles; changes in actual or assumed tax liabilities and tax law; expectations regarding tax exposures; anticipated reinvestment of future earnings and dividend policy; anticipated expenditures in regard to our benefit plans; future acquisitions and integration and anticipated benefits from acquisitions and dispositions; anticipated economic benefits and expected costs of restructuring programs; our ability to repay our indebtedness; our intentions regarding the use of cash; expectations regarding legal and regulatory requirements, including environmental requirements, and our compliance thereto; and other statements that are not historical facts.*

*Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various important factors, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; our dependence upon our ability to respond to fluctuations in product demand; our ability to continuously innovate, to introduce new products in a timely manner, and to manage transitions to new product innovations effectively; customer order timing and other similar factors; disruptions or breaches in security of our or our third-party providers’ information technology systems; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; our ability to contain or reduce costs; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components and other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to additional costs and significant delays in shipments; production difficulties and product delivery delays or disruptions; our exposure to extensive medical device regulations, which may impede or hinder the approval, certification or sale of our products and, in some cases, may ultimately result in an inability to obtain approval or certification of certain products or may result in the recall or seizure of previously approved or certified products; potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations related to our business or products; actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards, and other requirements; our failure to implement new information technology systems successfully; changes in foreign currency rates; our failure to realize the full value of our intangible assets; our reliance on original equipment manufacturer customers; the loss of sales, or significant reduction in orders from, any major customers; increasing scrutiny and changing expectations from investors, customers, governments and other stakeholders and third parties with respect to corporate sustainability policies and practices; the effects of climate change and related regulatory responses; our exposure to the credit risk of some of our customers and in weakened markets; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future. Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 under the heading “Risk Factors”, as updated in our other filings with the Securities and Exchange Commission.*

*In this Quarterly Report on Form 10-Q, the words “expects,” “intends,” “anticipates,” “estimates,” “believes,” “future,” “plans,” “aims,” “would,” “could,” “should,” “potential,” “continues,” and similar words or expressions (as well as other words or expressions referencing future events, conditions, or circumstances) identify forward-looking statements. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Management and the Company disclaim any obligation to publicly update or revise any such forward-looking statements to reflect any changes in its expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required under applicable law.*

## Accounting Period

The interim consolidated financial statements of Novanta Inc. (the “Company”, “Novanta”, “we”, “us”, “our”) are prepared for each quarterly period ending on the Friday closest to the end of the calendar quarter, except for the fourth quarter which always ends on December 31.

## Business Overview

We are a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables us to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications.

## Reportable Segments

### *Reporting Segment Change*

During the fourth quarter of 2024, we updated our organizational structure and re-aligned our financial reporting structure under two reportable segments: Automation Enabling Technologies and Medical Solutions. Prior to the reorganization, our historical reportable segments were: Precision Medicine and Manufacturing, Robotics and Automation, and Medical Solutions. Prior period segment financial information has been recast to align with the new reportable segments.

We operate in two reportable segments: Automation Enabling Technologies and Medical Solutions. The reportable segments and their principal activities are summarized below.

### *Automation Enabling Technologies*

The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO<sub>2</sub> lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The segment serves highly demanding applications for advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures such as ophthalmology applications. The vast majority of the segment's product offerings are sold to OEM customers. The segment sells the majority of these products directly, utilizing a highly technical sales force, and also sells some indirectly, through resellers and distributors.

### *Medical Solutions*

The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (“RFID”) technologies, barcode identification technologies, thermal chart recorders, light and color measurement technologies, touch panel displays, and advanced motion control solutions. The vast majority of the segment's product offerings are sold to OEM customers. The segment sells the majority of these products directly, utilizing a highly technical sales force, and also sells some indirectly, through resellers and distributors.

## End Markets

We primarily operate in two end markets: the medical market and the advanced industrial market.

### *Medical Market*

For the six months ended June 27, 2025, the medical market accounted for approximately 54% of our revenue. Revenue from our products sold to the medical market is generally affected by hospital, life science, and other healthcare provider capital spending, growth rates of surgical procedures, changes in regulatory requirements and laws, demand level for life science automation technology, aggregation of purchasing by healthcare networks, changes in technology requirements, timing of OEM customers' product development and new product launches, changes in customer or patient preferences, and general demographic trends.

### *Advanced Industrial Market*

For the six months ended June 27, 2025, the advanced industrial market accounted for approximately 46% of our revenue. Revenue from our products sold to the advanced industrial market is affected by a number of factors, including changing technology requirements and preferences of our customers, productivity or quality investments in a manufacturing environment, the financial conditions of our customers, changes in regulatory requirements and laws, and general economic conditions. We believe that the PMI on manufacturing activities specific to different regions around the world may provide an indication of the impact of general economic conditions on our sales into the advanced industrial market.

### **Strategy**

Our strategy is to drive sustainable, profitable growth through short-term and long-term initiatives, including:

- disciplined focus on our diversified business model of providing functionality to long life-cycle OEM customer platforms in attractive medical and advanced industrial niche markets;
- improving our business mix to increase medical sales as a percentage of total revenue by:
  - introducing new products aimed at attractive medical applications, such as minimally invasive and robotic surgery, ophthalmology, patient monitoring, drug delivery, clinical laboratory testing and life science equipment;
  - deepening our key account management relationships with and driving cross selling of our product offerings to leading medical equipment manufacturers; and
  - pursuing complementary medical technology acquisitions;
- increasing our penetration of high growth advanced industrial applications, such as laser materials processing, intelligent end-of-arm robotic technology solutions, robotics, laser additive manufacturing, automation and metrology, by working closely with OEM customers to launch application specific products that closely match the requirements of each application;
- broadening our portfolio of enabling proprietary technologies and capabilities through increased investment in new product development, and investments in application development to further penetrate existing customers, while expanding the applicability of our solutions to new markets;
- broadening our product and service offerings through the acquisition of innovative and complementary technologies and solutions in medical and advanced industrial technology applications;
- expanding sales and marketing channels to reach new target customers;
- improving our existing operations to expand profit margins and improve customer satisfaction by implementing lean manufacturing principles, strategic sourcing across our major production sites, and optimizing and limiting the growth of our fixed cost base; and
- attracting, retaining, and developing world-class talented and motivated employees.

### **Significant Events and Updates**

#### *Acquisition of Keonn Technologies, S.L.*

On April 8, 2025, we acquired 100% of the outstanding stock of Keonn Technologies, S.L. (“Keonn”), a Barcelona, Spain-based leader in Radio-Frequency Identification (“RFID”) solutions for an initial purchase price of €65.1 million (\$71.4 million), net of cash acquired, including €4.1 million (\$4.5 million) estimated fair value of contingent consideration and €3.4 million (\$3.7 million) related to a purchase price holdback and customary closing and net working capital adjustments. The purchase includes up to €20.0 million (\$21.9 million) in contingent consideration payable upon the achievement of certain revenue targets through December 2027. In addition, we have granted equity totaling €9.0 million (\$9.9 million) to Keonn employees. Keonn is included in the Medical Solutions segment.

#### *Fourth Amended and Restated Credit Agreement*

On June 27, 2025, we entered into the Fourth Amended and Restated Credit Agreement. The Fourth Amended and Restated Credit Agreement amends and restates, in its entirety, the Third Amended and Restated Credit Agreement dated as of December 31, 2019 (the “Third Agreement”). The Fourth Amended and Restated Credit Agreement provides for an aggregate credit facility of approximately \$1.0 billion, comprised of a €65.3 million euro-denominated 5-year term loan facility (the “Euro Term Loans”), a \$75.0 million U.S. dollar denominated 5-year term loan facility (the “U.S. Term Loans”), and an \$850.0 million 5-year revolving credit

facility (the “Revolving Facility”, and together with the Euro Term Loans and the U.S. Term Loans, collectively, the “Senior Credit Facilities”). The Senior Credit Facilities mature in June 2030 and include an uncommitted “accordion” feature pursuant to which the commitments thereunder may be increased by an additional \$350.0 million in aggregate, subject to the satisfaction of certain customary conditions.

### ***Business Environment***

In recent years, the global economy has faced significant challenges, including inflation, supply chain disruptions, business slowdowns, labor shortages, and market volatility, and recently new and proposed tariffs announced by the U.S. Presidential Administration have introduced additional uncertainty. We address macroeconomic challenges by continuing to execute our strategy. There have been improvements in the supply chain with better on-time deliveries, and recent efforts have successfully addressed talent shortages. However, uncertainty remains about overall macroeconomic conditions due to geopolitical tensions and changes in trade policies.

Economic tensions and changes in trade policies, such as higher tariffs, retaliatory measures, renegotiated free trade agreements, changes in government funding, and the ongoing impact from prolonged inflationary pressures have impacted the global market for our products and the cost to manufacture.

## **Results of Operations for the Three and Six Months Ended June 27, 2025 Compared with the Three and Six Months Ended June 28, 2024**

### **Overview of Financial Results**

Total revenue of \$241.0 million for the three months ended June 27, 2025 increased \$5.2 million, or 2.2%, from the prior year period primarily due to revenue from our current year acquisition and an increase in revenue in the Automation Enabling Technologies segment, partially offset by a decrease in revenue in the remaining portions of the Medical Solutions segment. The net effect of our acquisition resulted in an increase in revenue of \$5.3 million, or 2.3%. In addition, foreign currency exchange rates favorably impacted our revenue by \$4.8 million, or 2.0%, for the three months ended June 27, 2025.

Total revenue of \$474.4 million for the six months ended June 27, 2025 increased \$7.6 million, or 1.6%, from the prior year period, primarily due to revenue from our current year acquisition and an increase in revenue in the Automation Enabling Technologies segment, partially offset by a decrease in revenue in the remaining portions of the Medical Solutions segment. The net effect of our acquisition resulted in an increase in revenue of \$5.3 million, or 1.1%. In addition, foreign currency exchange rates favorably impacted our revenue by \$3.3 million, or 0.7%, for the six months ended June 27, 2025.

Operating income of \$14.9 million for the three months ended June 27, 2025 decreased \$10.8 million, or 42.0%, from the prior year period. This decrease was attributable to an increase in restructuring, acquisition and related costs of \$10.0 million, an increase in selling, general and administrative expenses of \$2.3 million, and an increase in research and development and engineering expenses of \$1.6 million, partially offset by an increase in gross profit of \$3.1 million.

Operating income of \$47.3 million for the six months ended June 27, 2025 decreased \$4.0 million, or 7.8%, from the prior year period. This decrease was attributable to an increase in restructuring, acquisition and related costs of \$5.3 million, an increase in selling, general and administrative expenses of \$4.4 million, and an increase in research and development and engineering expenses of \$1.6 million, partially offset by an increase in gross profit of \$7.0 million.

Basic earnings per common share (“Basic EPS”) of \$0.12 for the three months ended June 27, 2025 decreased \$0.26 from the prior year period. Diluted earnings per common share (“Diluted EPS”) of \$0.12 for the three months ended June 27, 2025 decreased \$0.26 from the prior year period. The decreases were primarily due to a decrease in operating income.

Basic earnings per common share (“Basic EPS”) of \$0.71 for the six months ended June 27, 2025 decreased \$0.08 from the prior year period. Diluted earnings per common share (“Diluted EPS”) of \$0.71 for the six months ended June 27, 2025 decreased \$0.08 from the prior year period. The decreases were primarily due to a decrease in operating income and an increase in foreign exchange transaction losses, partially offset by a decrease in interest expense.

## Revenue

The following tables set forth external revenue by reportable segment for the periods noted (dollars in thousands):

	Three Months Ended		Increase (Decrease)	Percentage Change
	June 27, 2025	June 28, 2024		
Automation Enabling Technologies	\$ 121,672	\$ 116,729	\$ 4,943	4.2%
Medical Solutions	119,377	119,135	242	0.2%
Total	<u>\$ 241,049</u>	<u>\$ 235,864</u>	<u>\$ 5,185</u>	2.2%

	Six Months Ended		Increase (Decrease)	Percentage Change
	June 27, 2025	June 28, 2024		
Automation Enabling Technologies	\$ 244,839	\$ 234,118	\$ 10,721	4.6%
Medical Solutions	229,576	232,662	(3,086)	(1.3)%
Total	<u>\$ 474,415</u>	<u>\$ 466,780</u>	<u>\$ 7,635</u>	1.6%

### Automation Enabling Technologies

Automation Enabling Technologies segment revenue for the three months ended June 27, 2025 increased \$4.9 million, or 4.2%, versus the prior year period, primarily due to increased demand in robotics and automation products, partially offset by a decrease in demand in precision manufacturing products.

Automation Enabling Technologies segment revenue for the six months ended June 27, 2025 increased \$10.7 million, or 4.6% versus the prior year period, primarily due to increased demand in robotics and automation products, partially offset by a decrease in demand in precision manufacturing products.

### Medical Solutions

Medical Solutions segment revenue for the three months ended June 27, 2025 increased \$0.2 million, or 0.2%, versus the prior year period, primarily due to the net impact of \$5.3 million revenue contributions from the current year acquisition, and an increase in sales of advanced surgery products, partially offset by a decrease in sales of precision medicine products.

Medical Solutions segment revenue for the six months ended June 27, 2025 decreased \$3.1 million, or 1.3%, versus the prior year period, primarily due to a decrease in sales of precision medicine products, partially offset by net impact of \$5.3 million of revenue contributions from the current year acquisition and an increase in sales of advanced surgery products.

## Gross Profit and Gross Profit Margin

The following table sets forth the gross profit and gross profit margin for each of our reportable segments for the periods noted (dollars in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Gross profit:				
Automation Enabling Technologies	\$ 58,206	\$ 54,995	\$ 117,591	\$ 110,497
Medical Solutions	49,514	49,337	95,475	95,559
Unallocated	(974)	(643)	(1,966)	(1,951)
Total	<u>\$ 106,746</u>	<u>\$ 103,689</u>	<u>\$ 211,100</u>	<u>\$ 204,105</u>
Gross profit margin:				
Automation Enabling Technologies	47.8%	47.1%	48.0%	47.2%
Medical Solutions	41.5%	41.4%	41.6%	41.1%
Total	44.3%	44.0%	44.5%	43.7%

Gross profit and gross profit margin can be influenced by a number of factors, including product mix, pricing, volume, manufacturing efficiencies and utilization, costs for raw materials and outsourced manufacturing, trade tariffs, freight costs, headcount, inventory excess and obsolescence, and warranty expenses.

#### *Automation Enabling Technologies*

Automation Enabling Technologies segment gross profit for the three months ended June 27, 2025 increased \$3.2 million, or 5.8%, versus the prior year period, primarily due to an increase in both revenue and gross profit margin. Automation Enabling Technologies segment gross profit margin was 47.8% for the three months ended June 27, 2025, versus a gross profit margin of 47.1% for the prior year period. The increase in gross profit margin was primarily attributable to a favorable product mix, partially offset by higher tariff costs.

Automation Enabling Technologies segment gross profit for the six months ended June 27, 2025 increased \$7.1 million, or 6.4%, versus the prior year period, primarily due to an increase in both revenue and gross profit margin. Automation Enabling Technologies segment gross profit margin was 48.0% for the six months ended June 27, 2025, versus a gross profit margin of 47.2% for the prior year period. The increase in gross profit margin was primarily attributable to a favorable product mix, partially offset by higher tariff costs.

#### *Medical Solutions*

Medical Solutions segment gross profit for the three months ended June 27, 2025 increased \$0.2 million, or 0.4%, versus the prior year period, primarily due to an increase in both revenue and gross profit margin. Medical Solutions segment gross profit margin was 41.5% for the three months ended June 27, 2025, versus a gross profit margin of 41.4% for the prior year period. The increase in gross profit margin was primarily due to a prior year one-time inventory related charge associated with a product line closure, which resulted in a 2.1 percentage point reduction in prior year gross profit margin, partially offset by an unfavorable product mix.

Medical Solutions segment gross profit for the six months ended June 27, 2025 decreased \$0.1 million, or 0.1%, versus the prior year period, primarily due to a decrease in revenue, partially offset by an increase in gross profit margin. Medical Solutions segment gross profit margin was 41.6% for the six months ended June 27, 2025, versus a gross profit margin of 41.1% for the prior year period. The increase in gross profit margin was primarily due to a prior year one-time inventory related charge associated with a product line closure, and a prior year amortization of inventory fair value adjustment associated with our 2024 acquisition, partially offset by unfavorable product mix.

#### *Operating Expenses*

The following table sets forth operating expenses for the periods noted (in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Research and development and engineering	\$ 25,289	\$ 23,731	\$ 48,527	\$ 46,977
Selling, general and administrative	47,103	44,793	92,699	88,323
Amortization of purchased intangible assets	6,871	6,907	12,425	12,657
Restructuring, acquisition, and related costs	12,572	2,543	10,117	4,826
<b>Total</b>	<b>\$ 91,835</b>	<b>\$ 77,974</b>	<b>\$ 163,768</b>	<b>\$ 152,783</b>

#### *Research and Development and Engineering Expenses*

Research and Development and Engineering (“R&D”) expenses are primarily comprised of employee compensation related expenses and cost of materials for R&D projects. R&D expenses were \$25.3 million, or 10.5% of revenue, during the three months ended June 27, 2025, versus \$23.7 million, or 10.1% of revenue, during the prior year period.

R&D expenses were \$48.5 million, or 10.2% of revenue, during the six months ended June 27, 2025, versus \$47.0 million, or 10.1% of revenue, during the prior year period.

### *Selling, General and Administrative Expenses*

Selling, general and administrative (“SG&A”) expenses include costs for sales and marketing, sales administration, finance, human resources, legal, information systems, and executive management functions. SG&A expenses were \$47.1 million, or 19.5% of revenue, during the three months ended June 27, 2025, versus \$44.8 million, or 19.0% of revenue, during the prior year period. The increase in SG&A expenses, both in total dollars and as a percentage of revenue, was primarily driven by costs associated with planning and design phase of our enterprise resource planning (“ERP”) system implementation.

SG&A expenses were \$92.7 million, or 19.5% of revenue, during the six months ended June 27, 2025, versus \$88.3 million, or 18.9% of revenue, during the prior year period. The increase in SG&A expenses, both in total dollars and as a percentage of revenue, was primarily driven by costs related to the costs associated with planning and design phase of the ERP system implementation.

### *Amortization of Purchased Intangible Assets*

Amortization of purchased intangible assets, excluding amortization of developed technologies which is included in cost of revenue, was \$6.9 million, or 2.9% of revenue, during the three months ended June 27, 2025, versus \$6.9 million, or 2.9% of revenue, during the prior year period.

Amortization of purchased intangible assets, excluding amortization of developed technologies which is included in cost of revenue, was \$12.4 million, or 2.6% of revenue, during the six months ended June 27, 2025, versus \$12.7 million, or 2.7% of revenue, during the prior year period.

### *Restructuring, Acquisition, and Related Costs*

We recorded restructuring, acquisition, and related costs of \$12.6 million during the three months ended June 27, 2025, versus \$2.5 million during the prior year period. The increase in restructuring, acquisition and related costs was primarily due to expenses related to the 2025 restructuring program, and an increase in acquisition and related expenses related to our current year acquisition.

We recorded restructuring, acquisition, and related costs of \$10.1 million during the six months ended June 27, 2025, versus \$4.8 million during the prior year period. The increase in restructuring, acquisition and related costs was primarily due expenses related to the 2025 restructuring program, and an increase in acquisition and related expenses related to our current year acquisition, partially offset by a gain on the sale of an owned facility.

### *Operating Income (Loss) by Segment*

The following table sets forth operating income (loss) by segment for the periods noted (in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
<b>Operating Income (Loss)</b>				
Automation Enabling Technologies	\$ 26,874	\$ 21,519	\$ 58,363	\$ 45,449
Medical Solutions	6,625	18,149	20,654	34,168
Unallocated	(18,588)	(13,953)	(31,685)	(28,295)
<b>Total</b>	<u>\$ 14,911</u>	<u>\$ 25,715</u>	<u>\$ 47,332</u>	<u>\$ 51,322</u>

### *Automation Enabling Technologies*

Automation Enabling Technologies segment operating income was \$26.9 million, or 22.1% of revenue, during the three months ended June 27, 2025, versus \$21.5 million, or 18.4% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of \$3.2 million, a decrease in R&D expenses of \$0.7 million, and a decrease in SG&A expenses of \$0.6 million.

Automation Enabling Technologies segment operating income was \$58.4 million, or 23.8% of revenue, during the six months ended June 27, 2025, versus \$45.4 million, or 19.4% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of \$7.1 million, a decrease in restructuring, acquisition and related costs of \$3.8 million, a decrease in R&D expenses of \$1.3 million and a decrease in amortization expenses of \$0.8 million.

### *Medical Solutions*

Medical Solutions segment operating income was \$6.6 million, or 5.5% of revenue, during the three months ended June 27, 2025, versus \$18.1 million, or 15.2% of revenue, during the prior year period. The decrease in operating income was primarily due to an increase in restructuring, acquisition and related costs of \$6.8 million, an increase in SG&A expenses of \$2.2 million, and an increase of R&D expenses of \$2.3 million.

Medical Solutions segment operating income was \$20.7 million, or 9.0% of revenue, during the six months ended June 27, 2025, versus \$34.2 million, or 14.7% of revenue, during the prior year period. The decrease in operating income was primarily due to an increase in restructuring, acquisition and related costs of \$6.5 million, an increase in SG&A expenses of \$3.4 million, an increase in R&D expenses of \$3.0 million, and an increase in amortization expenses of \$0.6 million.

### *Unallocated*

Unallocated costs primarily represent costs of corporate and shared services functions that are not allocated to the operating segments, including certain restructuring and most acquisition costs. These costs for the three months ended June 27, 2025 increased \$4.6 million versus the prior year period. The increase in operating loss was primarily due to an increase in restructuring, acquisition and related charges of \$3.7 million.

These costs for the six months ended June 27, 2025 increased \$3.4 million versus the prior year period. The increase in operating loss was primarily due to an increase in restructuring, acquisition and related charges of \$2.6 million, and an increase in SG&A expenses of \$0.9 million.

### *Other Income and Expense Items*

The following table sets forth other income and expense items for the periods noted (in thousands):

	Three Months Ended		Six Months Ended	
	June 27, 2025	June 28, 2024	June 27, 2025	June 28, 2024
Interest income (expense), net	\$ (5,815)	\$ (8,266)	\$ (11,459)	\$ (16,520)
Foreign exchange transaction gains (losses), net	\$ (2,744)	\$ (264)	\$ (3,112)	\$ (585)
Other income (expense), net	\$ (563)	\$ (55)	\$ (554)	\$ (171)

### *Interest Income (Expense), Net*

Net interest expense was \$5.8 million for the three months ended June 27, 2025, versus \$8.3 million for the prior year period. The decrease in net interest expense was primarily due to a decrease in the average debt levels under our senior credit facilities and a decrease in the weighted average interest rate. The weighted average interest rate on our senior credit facilities was 5.35% during the three months ended June 27, 2025, versus 6.74% during the prior year period.

Net interest expense was \$11.5 million for the six months ended June 27, 2025, versus \$16.5 million for the prior year period. The decrease in net interest expense was primarily due to a decrease in the average debt levels under our senior credit facilities and a decrease in the weighted average interest rate. The weighted average interest rate on our senior credit facilities was 5.50% during the six months ended June 27, 2025, versus 6.64% during the prior year period.

### *Foreign Exchange Transaction Gains (Losses), Net*

Foreign exchange transaction gains (losses) were \$(2.7) million for the three months ended June 27, 2025 versus \$(0.3) million for the prior year period. The increase in net foreign exchange transaction losses was primarily due to changes in the value of the U.S. Dollar against the British Pound and Euro, and realized losses on foreign currency contracts.

Foreign exchange transaction gains (losses) were \$(3.1) million for the six months ended June 27, 2025 and \$(0.6) million for the prior year period. The increase in net foreign exchange transaction losses was primarily due to changes in the value of the U.S. Dollar against the British Pound and Euro, and realized losses on foreign currency contracts.

### *Other Income (Expense), Net*

Net other expense was nominal for the three and six months ended June 27, 2025 and the three and six months ended June 28, 2024.

### ***Income Tax Provision (Benefit)***

Our effective tax rate for the three months ended June 27, 2025 was 22.3%, versus 19.7% for the prior year period. Our effective tax rate of 22.3% for the three months ended June 27, 2025 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated U.S. tax benefits for Foreign Derived Intangible Income (“FDII”) and R&D tax credits, and U.K. patent box deductions; partially offset by various non-deductible transaction-related and compensation expenses and uncertain tax position accruals.

Our effective tax rate for the three months ended June 28, 2024 of 19.7% differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions and R&D tax credits, partially offset by disallowed compensation deductions, uncertain tax position accruals, and Pillar Two inclusion.

Our effective tax rate for the six months ended June 27, 2025 was 20.2%, versus 16.5% for the prior year period. Our effective tax rate of 20.2% for the six months ended June 27, 2025 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated U.S. tax benefits for Foreign Derived Intangible Income (“FDII”) and R&D tax credits, and U.K. patent box deductions; partially offset by various non-deductible transaction-related and compensation expenses and uncertain tax position accruals.

Our effective tax rate of 16.5% for the six months ended June 28, 2024 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions, R&D tax credits and windfall tax benefits upon vesting of certain share-based compensation awards, partially offset by disallowed compensation deductions, uncertain tax position accruals, and Pillar Two inclusion.

On December 12, 2022, the EU member states agreed to implement the Organization for Economic Co-operation and Development’s (“OECD”) Pillar Two Model Rules. These rules, which impose a global corporate minimum income tax rate of 15%, have been enacted or introduced in proposed legislation in numerous countries worldwide, including many jurisdictions in which we operate. Additional countries are actively considering changes to their tax laws to adopt certain parts of the OECD’s proposals. We fall under the transitional safe harbor rules in the majority of jurisdictions in which we operate and are therefore not subject to Pillar Two global minimum tax in those jurisdictions. Where we cannot apply the safe harbor rules, we have estimated the impact of this minimum tax in our effective tax rate analysis. We continue to closely monitor the progression of legislative activities.

On July 4, 2025, the U.S. enacted H.R.1 - One Big Beautiful Bill Act (the “Act”). The Act contains numerous income tax provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act and modifications to the international tax framework. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We are currently assessing its impact on our consolidated financial statements.

### **Liquidity and Capital Resources**

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing, and financing activities. Our primary ongoing cash requirements are funding operations, capital expenditures, investments in businesses, and repayment of our debt and related interest payments. Our primary sources of liquidity are cash flows from operations and borrowings under our revolving credit facility. We believe our future operating cash flows will be sufficient to meet our future operating and capital expenditure cash needs for the foreseeable future, including at least the next 12 months. The availability of borrowing capacity under our revolving credit facility provides another potential source of liquidity for any future capital expenditures and other liquidity needs. In addition, we have the ability to expand our borrowing capacity by up to \$350.0 million by exercising the accordion option under our revolving credit agreement. We may also seek to raise additional capital, which could be in the form of bonds, convertible debt or preferred or common equity, to fund business development activities or other future investing cash requirements, subject to approval by the lenders in the Fourth Amended and Restated Credit Agreement (as amended, the “Credit Agreement”). There is no assurance that such capital will be available on reasonable terms or at all.

Significant factors affecting the management of our ongoing cash requirements are the adequacy of available bank lines of credit and our ability to attract long term capital with satisfactory terms. The sources of our liquidity are subject to all of the risks of our business and could be adversely affected by, among other factors, risks associated with events outside of our control, such as economic consequences of geopolitical conflicts, monetary, fiscal, tax or trade policy changes in the U.S. and other countries and their impact on the global financial markets, a decrease in demand for our products, our ability to integrate current and future acquisitions, deterioration in certain financial ratios, availability of borrowings under our revolving credit facility, and other market changes in general. See “Risks Relating to Our Common Shares and Our Capital Structure” included in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Our cash requirements primarily consist of principal and interest payments associated with our Senior Credit Facilities (as defined below), operating and finance leases, purchase commitments, and pension obligations. Such contractual obligations are described in our Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Our ability to make payments on our indebtedness and to fund our operations may be dependent upon the operating income and the distribution of funds from our subsidiaries. However, as local laws and regulations and/or the terms of our indebtedness restrict certain of our subsidiaries from paying dividends and transferring assets to us, there is no assurance that our subsidiaries will be permitted to provide us with sufficient dividends, distributions or loans when necessary.

As of June 27, 2025, \$67.1 million of our \$109.9 million cash and cash equivalents was held by subsidiaries outside of Canada and the U.S. Generally, our intent is to use cash held in these foreign subsidiaries to fund our local operations or acquisitions by those local subsidiaries and to pay down borrowings under our Senior Credit Facilities. Approximately \$171.0 million of our outstanding term loan and revolver borrowings under our Senior Credit Facilities were held in our subsidiaries outside of Canada and the U.S. as of June 27, 2025. Additionally, we may use intercompany loans to address short-term cash flow needs for various subsidiaries.

### Senior Credit Facilities

On June 27, 2025, we entered into the Fourth Amended and Restated Credit Agreement (the “Credit Agreement”), consisting of a €65.3 million euro-denominated 5-year term loan facility (the “Euro Term Loans”, a \$75.0 million U.S. Dollar denominated 5-year term loan facility (the “U.S. Term Loans”), and an \$850.0 million 5-year revolving credit facility (the “Revolving Facility”, and together with the Euro Term Loans and the U.S. Term Loans, collectively, the “Senior Credit Facilities”). The Senior Credit Facilities mature in June 2030 and include an uncommitted “accordion” feature pursuant to which the commitments thereunder may be increased by an additional \$350.0 million in aggregate, subject to the satisfaction of certain customary conditions.

The term loan facilities require quarterly scheduled principal repayments of €1.1 million beginning in September 2025 (with respect to the Euro Term Loans), and \$0.5 million beginning in September 2026, increasing to \$0.9 million in September 2027 (with respect to the U.S. Term Loans), with the remaining principal balance of the term loans due on June 27, 2030, if the maturity date of the term loan facility is not otherwise extended. We may make additional principal payments at any time, which will reduce the next quarterly installment payment due. We may pay down outstanding borrowings under our revolving credit facility with cash on hand and cash generated from future operations at any time.

As of June 27, 2025, we had \$151.6 million term loans and \$313.5 million revolver borrowings outstanding under our Senior Credit Facilities. Borrowings under the Credit Agreement bear interest at the Base Rate (as defined in the Credit Agreement) plus a margin ranging between zero and 0.75% per annum, determined by reference to the our consolidated leverage ratio, or SOFR, SONIA or EURIBOR, as applicable, plus a margin ranging between 1.00% and 1.75% per annum, determined by reference to our consolidated leverage ratio. In addition, we are obligated to pay a commitment fee on the unused portion of the Revolving Facility. As of June 27, 2025, we had outstanding borrowings under the Credit Agreement denominated in Euro and U.S. dollars of \$171.0 million and \$294.1 million, respectively.

The Credit Agreement contains various covenants that we believe are usual and customary for this type of agreement, including a maximum consolidated leverage ratio and a minimum consolidated fixed charge coverage ratio (as defined in the Credit Agreement). The following table summarizes these financial covenants and our compliance therewith as of June 27, 2025:

	Requirement	Actual
Maximum consolidated leverage ratio <sup>(1)</sup>	3.50	1.93
Minimum consolidated fixed charge coverage ratio	1.25	5.29

<sup>(1)</sup> Maximum consolidated leverage ratio shall be increased to 4.00 for four consecutive quarters following a designated acquisition, as defined in the Fourth Amended and Restated Credit Agreement.

### Share Repurchase Plans

Our Board of Directors may approve share repurchase plans from time to time. Under these repurchase plans, shares may be repurchased at our discretion based on ongoing assessment of the capital needs of the business, the market price of our common shares, and general market conditions. Shares may also be repurchased through an accelerated share purchase agreement, on the open market or in privately negotiated transactions in accordance with applicable federal securities laws. Repurchases may be made under certain SEC regulations, which would permit common shares to be repurchased when we would otherwise be prohibited from doing so under insider trading laws. While the share repurchase plans are generally intended to offset dilution from equity awards granted to our employees and directors, the plans do not obligate us to acquire any particular amount of common shares. No time limit is

typically set for the completion of the share repurchase plans, and the plans may be suspended or discontinued at any time. We expect to fund share repurchases through cash on hand and cash generated from operations.

In February 2020, our Board of Directors approved a share repurchase plan (the “2020 Repurchase Plan”) authorizing the repurchase of \$50.0 million worth of common shares. Share repurchases have been made under the 2020 Repurchase Plan pursuant to Rule 10b-18 under the Securities Exchange Act of 1934. We repurchased 46 thousand shares under the 2020 Repurchase Plan for an aggregate purchase price of \$6.2 million and average price of \$134.54 per share during the six months ended June 27, 2025. We had \$43.3 million available for share repurchases under the 2020 Repurchase Plan as of June 27, 2025.

#### ***Cash Flows for the Six Months Ended June 27, 2025 and June 28, 2024***

The following tables summarize our cash flows, cash and cash equivalents, and unused and available funds under our revolving credit facility for the periods indicated (in thousands):

	<b>Six Months Ended</b>	
	<b>June 27, 2025</b>	<b>June 28, 2024</b>
Net cash provided by operating activities	\$ 46,756	\$ 73,924
Net cash used in investing activities	\$ (65,308)	\$ (202,552)
Net cash provided by financing activities	\$ 12,101	\$ 121,440
	<b>June 27, 2025</b>	<b>December 31, 2024</b>
Cash and cash equivalents	\$ 109,912	\$ 113,989
Unused and available funds under the revolving credit facility	\$ 536,505	\$ 346,249

#### ***Operating Cash Flows***

Cash provided by operating activities was \$46.8 million for the six months ended June 27, 2025, versus \$73.9 million for the prior year period. Cash provided by operating activities for the six months ended June 27, 2025 decreased from the prior year period primarily as a result of an increase in inventory and higher cash paid for income taxes.

#### ***Investing Cash Flows***

Cash used in investing activities was \$65.3 million for the six months ended June 27, 2025, primarily driven by \$63.2 million of cash considerations (net of cash acquired) paid for our 2025 acquisition and \$7.7 million for capital expenditures, partially offset by \$5.5 million of cash received from the sale of properties.

Cash used in investing activities was \$202.6 million for the six months ended June 28, 2024, primarily related to the \$191.2 million of cash considerations (net of cash acquired) paid for our 2024 acquisition and \$11.4 million for capital expenditures.

We expect to use an aggregate of approximately \$15 million to \$20 million in 2025 for capital expenditures related to investments in new property, plant and equipment for our existing businesses.

#### ***Financing Cash Flows***

Cash provided by financing activities was \$12.1 million for the six months ended June 27, 2025, primarily driven by \$72.8 million of borrows under our revolving credit facility to fund our 2025 acquisition, partially offset by \$41.0 million of term loan and revolving credit facility repayments, \$7.2 million of payroll tax payments upon vesting of share-based compensation awards and \$6.2 million related to the repurchase of common shares.

Cash provided by financing activities was \$121.4 million for the six months ended June 28, 2024, primarily driven by \$198.0 million of borrowings under our revolving credit facility to fund our 2024 acquisition, partially offset by \$67.3 million of term loan and revolving credit facility repayments and \$8.9 million of payroll tax payments upon vesting of share-based compensation awards.

#### **Critical Accounting Policies and Estimates**

The critical accounting policies that we believe impact significant judgments and estimates used in the preparation of our consolidated financial statements presented in this periodic report on Form 10-Q are described in our Management’s Discussion and

Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. There have been no material changes to our critical accounting policies and estimates through June 27, 2025 from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

#### **Recent Accounting Pronouncements**

See Note 1 to Unaudited Interim Consolidated Financial Statements.

#### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Our primary market risk exposures are foreign currency exchange rate fluctuations and interest rate sensitivity. During the three months ended June 27, 2025, there have been no material changes to the information included under Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

#### **Item 4. Controls and Procedures**

##### **Evaluation of Disclosure Controls and Procedures**

As required by Rule 13a-15(b) under the Securities and Exchange Act of 1934 (the “Exchange Act”), our management carried out an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of June 27, 2025, the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 27, 2025.

##### **Changes in Internal Control Over Financial Reporting**

There has been no change to our internal control over financial reporting during the fiscal quarter ended June 27, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## **PART II—OTHER INFORMATION**

### **Item 1. Legal Proceedings**

We are subject to various legal proceedings and claims that arise in the ordinary course of business. We do not believe that the outcome of these claims will have a material adverse effect upon our financial condition or results of operations but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect upon our financial condition or results of operations.

### **Item 1A. Risk Factors**

Our operations and financial results are subject to various risks and uncertainties, including the factors discussed in Part I, Item 1A, Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2024, which could adversely affect our business, financial conditions and future results. Other than the risk factor set forth below, there have been no material changes from the risk factors discussed in our Annual Report.

#### **Our results of operations could be adversely affected by economic and political conditions and the effects of these conditions on our customers' businesses, capital expenditures and levels of business activities.**

A large portion of our product sales are dependent on our customers' need for increased capacity, productivity and cost saving initiatives, improved product quality and performance, and new investments. Weaknesses in our end markets could negatively impact our revenue and gross margin and consequently have a material adverse effect on our business, financial condition and results of operations. A severe and/or prolonged overall economic downturn or a negative or uncertain political climate could lead to weaknesses in our end markets and adversely affect our customers' financial condition and the timing or levels of our customers' capital expenditures or business activities. We have experienced significant cyclical end market fluctuations in the past. For example, diminished growth expectations, economic and political uncertainty in regions across the globe and effects of the COVID-19 pandemic adversely impacted our customers' financial condition and ability to maintain product order levels and reduced the demand for our products in 2020, and other pandemics and public health crises could have similar consequences. Political conditions, including new and changing laws or tariffs, regulations, government funding, executive orders and enforcement priorities, may impact customer budgets and create uncertainty about how such laws and regulations will be interpreted and applied, which may impact customer demand and adversely impact our business. For example, changes in the regulatory environment affecting life sciences, bioprocessing, and pharmaceutical companies, and reduced headcount and budget allocations to government agencies that fund research and development activities, such as the U.S. Food and Drug Administration ('FDA'), U.S. National Institutes of Health ("NIH"), or targeted headcount reductions or cancellations of certain grants or contracts by the U.S. federal government, could adversely affect our business or results of operations. In addition, certain sub-segments of the advanced industrial market that we serve, including the microelectronics and industrial capital equipment sector, are cyclical and have historically experienced periods of oversupply, resulting in downturns in demand for capital equipment in which many of our products are used. It is difficult to predict the timing, length and severity of these downturns and their impact on our business. Further, our order levels or results of operations for a given period may not be indicative of order levels or results of operations for subsequent periods. For the foreseeable future, our operations will continue to depend upon industries that are subject to market cycles which, in turn, could adversely affect the market demand for our products.

We have also faced increases in inflationary conditions in materials and components. These inflationary conditions have caused us to increase prices; however, such price increases may not be accepted by our customers or may not adequately offset the increases in our costs, thereby negatively affecting our results of operations. Changes in global economic conditions, including inflationary conditions, could also shift demand for products or services for which we do not have competitive advantages. This could negatively affect the amount of business that we are able to obtain. In addition, if we are unable to successfully anticipate changes in economic and political conditions, we may be unable to effectively plan for and respond to those changes, and our business could be negatively affected.

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

### **Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

None.

**Item 5. Other Information**

a) *Disclosure in lieu of reporting on a Current Report on Form 8-K*

None.

b) *Material changes to the procedures by which security holders may recommend nominees to the board of directors.*

None.

c) *Rule 10b5-1 Trading Plans*

No officers or directors adopted, modified, and/or terminated a “Rule 10b5-1 trading agreement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K, during the three months ended June 27, 2025.

## Item 6. Exhibits

Exhibit Number	Exhibit Description	Incorporated by Reference				Filed/ Furnished Herewith
		Form	File No.	Exhibit	Filing Date	
3.1	<a href="#">Certificate and Articles of Continuance of the Registrant, dated March 22, 1999</a>	S-3	333-202597	3.1	03/09/2015	
3.2	<a href="#">By-Laws of the Registrant, as amended</a>	10-K	001-35083	3.2	03/01/2021	
3.3	<a href="#">Articles of Reorganization of the Registrant, dated July 23, 2010</a>	8-K	000-25705	3.1	07/23/2010	
3.4	<a href="#">Articles of Amendment of the Registrant, dated May 26, 2005</a>	10-K	001-35083	3.4	3/1/2023	
3.5	<a href="#">Articles of Amendment of the Registrant, dated December 29, 2010</a>	8-K	000-25705	3.1	12/29/2010	
3.6	<a href="#">Articles of Amendment of the Registrant, dated May 11, 2016</a>	8-K	001-35083	10.1	05/12/2016	
3.7	<a href="#">Articles of Amendment of the Registrant, dated April 29, 2022</a>	10-Q	001-35083	3.6	05/10/2022	
10.1	<a href="#">Fourth Amended and Restated Credit Agreement, dated as of June 27, 2025, by and among the Company, Novanta Corporation, Novanta UK Investments Holding Limited, Novanta Europe GmbH, Bank of America, N.A., as Administrative Agent, Swing Line Lender, L/C Issuer and lender, BofA Securities, Inc., as joint lead arranger and joint book runner, JP Morgan Chase Bank, N.A., as joint lead arranger, joint book runner, co-syndication agent and lender, Wells Fargo Securities LLC, as joint lead arranger and joint book runner, Wells Fargo Bank, National Association, as co-syndication agent and lender, PNC Capital Markets LLC, as joint lead arranger and joint book runner, PNC Bank, National Association, as co-syndication agent and lender, U.S. Bank National Association, as joint lead arranger and co-syndication agent, Silicon Valley Bank, a Division of First Citizens Bank &amp; Trust Company, as documentation agent and lender, Citibank N.A. as lender, and the other parties thereto.</a>	8-K	001-35083	10.1	07/02/2025	
31.1	<a href="#">Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a>					*
31.2	<a href="#">Chief Financial Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a>					*
32.1	<a href="#">Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>					**
32.2	<a href="#">Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>					**
101.INS	Inline eXtensible Business Reporting Language (XBRL) Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.					*
101.SCH	Inline XBRL Taxonomy Extension Schema Document					*
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)					*

† Certain schedules or appendices to this exhibit have been omitted pursuant to Regulation S-K Item 601(a)(5). A copy of any omitted schedule will be furnished to the Securities and Exchange Commission or its staff upon request.

\* Filed herewith

\*\* Furnished herewith

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

### Novanta Inc. (Registrant)

Name	Title	Date
/s/ Matthijs Glastra	Chair of the Board of Directors and Chief Executive Officer	August 5, 2025
<b>Matthijs Glastra</b>		
/s/ Robert J. Buckley	Chief Financial Officer	August 5, 2025
<b>Robert J. Buckley</b>		

**CERTIFICATION PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002  
CERTIFICATIONS**

I, Matthijs Glastra, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Novanta Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

August 5, 2025

/s/ Matthijs Glastra

Matthijs Glastra

Chief Executive Officer

---

**CERTIFICATION PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002  
CERTIFICATION**

I, Robert J. Buckley, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Novanta Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

August 5, 2025

/s/ Robert J. Buckley

Robert J. Buckley

Chief Financial Officer

---

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Novanta Inc. (the "Company") on Form 10-Q for the period ended June 27, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Matthijs Glastra, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

- (1) the Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

August 5, 2025

/s/ Matthijs Glastra

Matthijs Glastra

*Chief Executive Officer*

---

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Novanta Inc. (the "Company") on Form 10-Q for the period ended June 27, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Robert J. Buckley, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

- (1) the Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

August 5, 2025

/s/ Robert J. Buckley

Robert J. Buckley

*Chief Financial Officer*

---